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Macrophage and Endothelial-Specific Role of p38α MAPK in Atherosclerosis 
Rozina Kardakaris, University of Cologne, Cologne, Germany 
The aim of my PhD project was to investigate the macrophage and endothelial-specific role of the 
p38α MAPK signaling pathway in the development of Atherosclerosis.  
There are four p38 MAP kinases in mammals: α, β, γ and δ. Among all p38 MAPK isoforms, p38α is 
the best characterised, is expressed in most cell types and is the predominant form of p38 expressed 
in inflammatory cells. p38 MAPKs are strongly activated in vivo by environmental stresses and 
inflammatory cytokines. The canonical activation of p38 MAPKs occurs via dual phosphorylation of 
their Thr-Gly-Tyr motif in the activation loop, by MKK3 and MKK6. But it can also occur by an MKK 
independent mechanism through the adaptor protein TAB1 and by a TCR mediated mechanism by 
phosphorylation of Tyr323, in T cells. Activation of p38 MAPKs can lead to a variety of responses 
through phosphorylation of downstream kinases like MK2 or transcription factors like ATF2. 
Atherosclerosis, a progressive inflammatory disease of the medium and large arteries characterized 
by intense immunological activity, comprises the primary underlying cause of about 50% of 
cardiovascular disease related deaths in the western world today. p38α MAPK, which was first 
identified in studies on inflammation, is activated in response to various stress factors, including 
inflammatory cytokines and oxLDL, a major factor contributing to the onset of atherosclerosis. Here I 
addressed the role of p38α MAPK, the most physiologically relevant p38 MAPK, in macrophages and 
endothelial cells in the pathogenesis of atherosclerosis in vivo. Both macrophage and endothelial cell-
ablation of p38α MAPK, achieved by taking advantage of the Cre-loxP recombination system, did not 
lead to any significant reduction or aggravation of atherosclerosis plaque formation compared to 
ApoE-/- mice fed with a cholesterol-rich ‘western diet’ for 10 weeks. This result is contradictory to 
studies carried out in vitro thus far with p38 small molecule inhibitors, but also recently in vivo where 
p38α MAPK ablation in macrophages led to plaques with decreased collagen content and increased 
necrotic core formation. Thus, macrophage and endothelial cell-specific signaling of p38α MAPK, 
contrary to general belief, does not appear to either promote or reduce the pathogenesis of 
atherosclerosis. 
In parallel, I also generated two new mouse models of p38α MAPK, p38αCA and p38αKD, by 
homologous recombination. In the p38αCA model, that expresses a constitutively active form of p38α 
MAPK, we took advantage of the ROSA26 locus that allows ubiquitous expression of a protein, to 
target a mutant form of p38α under the control of Cre recombinase. p38αKD, expressing a kinase 
dead form of p38α MAPK also under the control of Cre recombinase, was generated by targeting 
exon 2 of the p38α locus with a mutated exon 2, rendering it catalytically inactive. Both of these 
models, which preliminary results suggest are functional, are very useful genetic tools for the further 
elucidation of the p38α MAPK pathway with respect to many disease models, like cancer, 
cardiovascular and other diseases. 
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Die Makrophagen- und Endothelspezifische Rolle der p38α MAPK in der Arteriosklerose 
Rozina Kardakaris, University of Cologne, Cologne, Germany 
Das Ziel meiner Dissertation war es, die makrophagen- und endothelspezifische Rolle des p38α 
MAPK Signaltransduktionsweges während der Entwicklung der Arteriosklerose zu untersuchen.  
In Säugern gibt es vier p38 MAP-Kinasen: a, b, g und d. Von allen p38 MAPK Isoformen ist p38α die 
am besten charakterisierte, die in den meisten Zelltypen exprimierte und die hauptsächliche Form von 
p38 in Zellen, die an einer Entzündung beteiligt sind. p38 MAP-Kinasen werden in vivo stark durch 
entzündliche Zytokine und Stress durch Umwelteinflüsse aktiviert. Die kanonische Aktivierung von 
p38 MAP-Kinasen erfolgt durch Doppelphosphorylierung ihres Thr-Gly-Tyr-Motivs in der 
Aktivierungsschleife durch MKK3 und MKK6. Aber sie kann auch auf MKK-unabhängige Weise über 
das Adaptorprotein TAB1 und einen TCR-abhängigen Mechanismus durch Phosphorylierung von 
Tyr323 in T-Zellen erfolgen. Aktivierung von p38 MAP-Kinasen kann zu einer ganzen Reihe von 
Reaktionen durch Phosphorylierung nachgeschalteter Kinasen, wie z.B. MK2 oder 
Transkriptionsfaktoren, wie etwa ATF2 führen. 
Arteriosklerose, eine fortschreitende entzündliche Krankheit der mittleren und grossen Arterien, die 
durch starke immunologische Aktivität gekennzeichnet ist, ist die zugrundeliegende Hauptursache für 
etwa die Hälfte aller Todesfälle, die heutzutage von Herz-Kreislauferkrankungen in der westlichen 
Welt herrühren. p38a MAPK, die zuerst in Studien über Entzündung identifiziert wurde, wird durch 
verschiedenste Umweltfaktoren aktiviert, u.a. entzündliche Zytokine und oxLDL, einem Hauptfaktor 
für Arteriosklerose. In dieser Arbeit behandelte ich die Rolle von p38α MAPK, der physiologisch 
relevantesten p38 MAPK, in Makrophagen und Endothelzellen für die Pathogenese der 
Arteriosklerose in vivo. Weder die makrophagen- noch die endothelzellspezifische Ablation von p38α 
MAPK, herbeigeführt durch das Cre-loxP-System, führte zu einer signifikanten Reduktion oder 
Vermehrung von arteriosklerotischen Plaques im Vergleich zu ApoE-/- Mäusen auf cholesterinreicher 
„westlicher Diät“ für 10 Wochen. Dieses Ergebnis widerspricht in vitro-Studien mit p38-spezifischen 
Inhibitoren, aber auch neueren in vivo-Resultaten, in denen p38α-Ablation zu kleineren Plaques mit 
weniger Collagengehalt und Bildung von grösseren nekrotischen Kernen führte. Makrophagen- und 
endothelspezifische p38α-Signaltransduktion scheint daher die Pathogenese der Arteriosklerose 
weder zu fördern noch zu reduzieren. 
Parallel dazu generierte ich zwei neue Mausmodelle für die p38α MAP-Kinase durch homologe 
Rekombination, p38αCA und p38αKD. Für das p38αCa-Modell, welches eine konstitutiv aktive Form 
der p38α MAPK exprimiert, machten wir uns den ROSA26-Lokus zu Nutze, der ubiquitäre Expression 
eines Proteins ermöglicht, und in den wir eine mutierte Form der p38α MAPK unter der Kontrolle von 
Cre-Rekombinase setzten. p38KD, welche eine Kinase-inaktive Form von p38α unter der Kontrolle 
der Cre-Rekombinase darstellt, wurde durch Einführung eines mutierten Exon 2 in den p38α-Lokus 
hergestellt, welches die katalytische Funktion der Kinase inaktiviert. Beide Modelle, die ersten 
Ergebnissen nach funktional sind, stellen äusserst nützliche genetische Werkzeuge dar, um den p38α 
MAPK-Signaltransduktionsweg weiter zu untersuchen, vor allem im Hinblick auf zahlreiche 
Krankheitsmodelle, wie Krebs, Herz-Kreislauf- und andere Erkrankungen. 
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1. Introduction 
1.1 Mitogen-Activated Protein Kinases (MAPKs) 
Cellular behavior in response to extracellular stimuli is mediated through intracellular 
signaling pathways such as mitogen-activated protein kinase (MAPKs) pathways 1. 
MAPKs are evolutionary conserved enzymes connecting cell-surface receptors to 
critical regulatory targets within cells. They respond to chemical and physical 
stresses, thereby controlling cell-survival and adaptation 2. There are 14 MAPKs in 
mammalian cells that can be divided into four distinct subgroups, and are 60-70% 
identical to each other 3: (1) extracellular signal-regulated kinases (ERKs 1 & 2) 
which were the first to be discovered, (2) c-jun N-terminal or stress-activated protein 
kinases (JKNK/SAPK), (3) the p38 group of protein kinases and (4) atypical MAPKs 
such as ERK3, ERK5 and ERK8 4,5. Each MAPK pathway can be activated by 
different stimuli, and lead to different responses. In general, the ERKs are activated 
by mitogenic and proliferative stimuli, whereas the JNKs and p38 MAPKs respond to 
environmental stress, including ultraviolet light, heat, osmotic shock and 
inflammatory cytokines 6. Cellular responses for ERKs include cell proliferation, 
transformation and differentiation, whereas the activation of JNKs and p38 MAPKs 
can lead to apoptosis, stress responses and inflammation 7 (Fig. 1). 
 
1.1.1 MAPK Signal Transduction 
MAPK activity is regulated through three-tiered cascades composed of a MAPK, 
MAPK kinase (MAPKK, MKK or MEK) and a MAPKK kinase or MEK kinase 
(MAPKKK or MEKK) 8 (Fig. 1). Activation of MAPKs occurs through phosphorylation. 
A common feature of all MAPK isoforms is the phosphorylation of both threonine 
(Thr) and tyrosine (Tyr) residues by a dual-specificity serine-threonine MAPK kinase 
that, in turn, is phosphorylated and activated by an upstream MKK kinase. All 
MAPKs share the amino acid sequence Thr-Xxx-Tyr in which X differs depending on 
the MAPK isoform. The amino acid X is glutamic acid (Glu), proline (Pro) and glycine 
(Gly) for ERK, JNK and p38 MAPK respectively. The Thr-Xxx-Tyr phosphorylation 
motif is localized in an activation loop near the ATP- and substrate-binding sites. The 
length of the activation loop also differs between the three MAPK families. 
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Phosphorylation occurs by an ordered addition of phosphate to the tyrosine then the 
threonine, with MKK dissociating from MAPK between each step 3,6,7. 
Once activated, MAPKs can phosphorylate and activate other kinases or nuclear 
proteins such as transcription factors in either the cytoplasm or the nucleus. This 
leads to an increase or decrease in the expression of certain target genes, resulting 
in a biological response. The variation in specificity within a pathway suggests that 
different extracellular signals can produce stimulus- and tissue – specific responses 
by activating one or more MAPK pathways 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Mitogen-activated protein 
kinases (MAPKs), which integrate and 
process various extracellular signals. The 
MAPK cascade consists of a series of 
three protein kinases — a MAPK and two 
upstream components, MAPK kinase 
(MAPKK or MEK) and MAPKK kinase 
(MAPKKK). ERK, extracellular signal-
regulated kinase; JNK, c-Jun N-terminal 
kinase. Image taken from Kumar, S. et al. 
2003, Nature Reviews Drug Discovery.  
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1.2 p38 MAPK 
Mammalian p38 MAPK, a 38 kDa protein, was originally identified as a molecular 
target of the pyridinyl imidazole class of compounds that were known to inhibit 
biosynthesis of inflammatory cytokines like interleukin-1 (IL-1) and tumor-necrosis 
factor (TNF) in lipopolysaccharide (LPS) and IL-1 stimulated human monocytes 1,9-
11. Four isoforms of p38 are known to exist in mammals, p38α, p38β, p38γ and 
p38δ. From these, p38α and p38β are 74% identical and widely expressed 12, 
whereas p38γ (63% identical to p38α) is predominantly expressed in the skeletal 
muscle 13 and p38δ  (61% identical to p38α) in the testes, pancreas and small 
intestine, as well as CD4+ T cells 14,15. They have the same preference for activating 
downstream targets by phosphorylating serines and/or threonines that precede 
prolines, e.g. activating transcription factor 2 (ATF2) and MAPK activated protein 
kinase (MAPKAPK2), but, despite their high overall degree of homology they seem 
to have different fine specificities for substrates, at least in vitro 13-15. 
 
1.2.1 p38 MAPK Activation and Downregulation 
p38 MAPK is mainly activated by dual phosphorylation on Thr180 and Tyr182 by the  
upstream MAPKKs MAP2K6 or otherwise MKK6 and MAP2K3 (MKK3), although the 
ability of these kinases to phosphorylate the various p38 isoforms varies. This is 
evidenced by the inability of MKK3 to effectively activate p38β while MKK6 can 
activate it potently despite 80% homology between these two MKKs 16. MKK4, an 
upstream kinase of JNK, has also been shown to aid in the activation of p38α and 
p38δ in specific cell types 17. MKKs are activated by several MAPKKKs, like 
apoptosis signal-regulating kinase-1 (ASK-1) or transforming growth factor β-
activated protein kinase 1 (TAK1), which in turn are activated by a wide variety of 
stimuli 18,19, underscoring the complex nature of these signal transduction pathways, 
which require the integration of multiple signals from different pathways (Fig. 2). 
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Figure 2. The complex nature of the p38 MAPK signal transduction pathway. Environmental 
stress and/or inflammatory cytokines activate MAPKKKs through a variety of signaling mechanisms. 
Activated MAPKKKs subsequently activate MAPKKs, which in turn activate MAPKs. Activated MAPKs 
then phosphorylate several substrates, such as transcription factors, other kinases and cytosolic 
proteins. These effector molecules are essential for cellular responses that include cytokine production 
and transcriptional regulation. In this figure, dotted lines represent indirect effects, and solid lines 
represent a direct effect. Image taken from Kumar, S. et al. 2003, Nature Reviews Drug Discovery. 
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Recently, a MAPKK-independent mechanism of p38α MAPK activation has been 
described. This involves association of the protein TAK1-binding protein 1 (TAB1), 
and intramolecular autophosphorylation of p38, independent of MAPKKs. This 
activation of p38 appears to be as efficient as activation by MAPKKs, like MKK6 20. 
Another MKK-independent mechanism of activation for p38α MAPK has been 
observed in T cells stimulated through the T-cell antigen receptor. In this system, 
p38α MAPK is activated by an alternative mechanism in which TCR-mediated 
stimulation activates proximal tyrosine kinases that results in the phosphorylation of 
p38α MAPK on a noncanonical activating residue, Tyr323. This phosphorylation 
activates p38α MAPK, probably by causing changes in its structural conformation, to 
phosphorylate third party substrates as well as its own Thr-Gly-Tyr motif 21, 22, 23. 
When p38 MAPKs are activated under physiological conditions, their activity is often 
transient despite the unchanging levels of protein throughout the stimulation. This 
means that activation is only dependant on phosphorylation, and thus 
dephosphorylation of p38, but also other MAPKs, plays an important role in their 
downregulation. The activity of p38 specifically has been shown to be downregulated 
by various protein phosphatases, such as protein phosphatase 2A 24. In vitro studies 
have also shown that it can be dephosphorylated by the dual –specificity 
phosphatases 16 (DUSP16) 25,26, and to a lesser extent by DUSP10 27. Recently, 
specifically for p38α, it was also shown to be dephosphorylated by DUSP1 28. 
 
1.2.2 p38 MAPK Downstream Targets 
The identification of downstream targets for p38 MAPKs has been assisted by the 
utilization of relatively specific pyridinyl imidazole inhibitors such as SB203580 and 
SB202190 29, 30. These compounds, which are mostly specific for p38α and p38β 
MAPKs, have been very important tools in the delineation of pathways in which 
these MAPKs are involved. Many p38 MAPK targets have been described, both in 
the cytoplasm and the nucleus, the vast majority of which fall into two categories, 
transcription factors and protein kinases, although some other proteins have also 
been described as p38 MAPK substrates (Fig. 1 and 2). Activation (or inhibition) of 
these substrates occurs via p38 MAPK. This phosphorylation is known to take place 
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in the cytoplasm where p38 MAPKs are located, although some evidence suggests 
that upon cell stimulation p38α MAPK translocates into the nucleus 31. 
 
1.2.2.1 Protein Kinase Substrates of p38 MAPKs 
The first p38α substrate identified was MAPKAPK2 (or MK2) 1,11,32. This substrate, 
along with its closely related family member MK3, were both shown to activate 
various substrates including small heat shock protein 27 (HSP27) 33, lymphocyte-
specific protein 1 (LSP1) 34, cAMP response element-binding protein (CREB) 35, 
transcription factor ATF1 35, SRF 36, and tyrosine hydroxylase 37. More recently, MK2 
has been found to phosophorylate tristetrapolin (TTP), a protein that is known to 
destabilize mRNA hinting at a role for p38 in mRNA stability 38. MNK1 is another 
substrate of p38 whose function is thought to reside in translational initiation due to 
the observation that MNK1 and MNK2 can phosphorylate eukaryotic initiation factor-
4e (eIF-4E) 39,40. p38 regulated/activated kinase (PRAK) is a p38α and/or p38β 
activated kinase that shares 20-30% sequence identity to MK2 and is thought to 
regulate HSP27 41. Mitogen- and stress-activated protein kinase-1 (MSK1) can be 
directly activated by p38 and ERK, and may mediate activation of CREB 42-44. p38 
is also thought to regulate S phase activation of histone 2B (H2B) promoter through 
OCA-S, a component of p38 45. 
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1.2.2.2 Transcription Factor Substrates of p38 MAPKs 
p38 MAPK is also capable of modulating gene expression by phosphorylating 
transcription factors directly and by activating other protein kinases (e.g. MNKs as 
described above) which then phosphorylate proteins involved in gene expression. 
Many transcription factors encompassing a broad range of action have been shown 
to be phosphorylated and subsequently activated by p38. Examples include ATF-1, 2 
and 6, SRF accessory protein (Sap1), CHOP, growth arrest and DNA damage 
inducible gene 153 (GADD153), p53, C/EBPβ, myocyte enhance factor 2C 
(MEF2C), MEF2A, MITF1, DDIT3, ELK1, NFAT, and high mobility group-box protein 
1 (HBP1) 31,35,46-56. An important cis-element, the activator protein-1 (AP-1) binding 
site appears to be influenced by p38 through several different mechanisms. ATF-2 is 
known to form heterodimers with Jun family transcription factors thereby directly 
associating with the AP-1 binding site 51. Another possible mechanism comes from 
the observation that a component of AP-1 is c-fos. C-fos is known to be SRE 
dependant and SRE is able to bind Ternary Complex Factor (TCF). Ternary 
Complex Factor is comprised of Sap-1a, a protein that is phosphorylated by p38. 
Thus, p38 indirectly regulates AP-1 activity. ERK and JNK can also mediate another 
component of the TCF called Elk-1 57. It is thought then that there is coordinated 
participation of the three MAP kinases in regulation of c-fos expression. Recently, 
the HBP1 transcription factor has been identified as a substrate for p38. HBP1 has 
been linked to G1 cell cycle arrest and inhibition of p38 has been shown to decrease 
HBP1 protein levels 53. 
 
1.2.2.3 Other Substrates of p38 MAPKs 
Other substrates of p38 MAPKs include metabolic enzymes like glycogen synthase 
or cytosolic phospholipase A2 (cPLA2) 58, 19, 59. Na+/H+ exchanger isoform 1 (NHE-
1), tau and keratin 8 have also been reported to be substrates of p38α MAPK, just 
like stathmin. Taken together, this vast collection of substrates suggests that the p38 
pathway is involved in a wide and diverse variety of functions. 
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1.2.3 Physiological Functions of p38 MAPKs 
Taking into consideration the wide range of substrates linked to p38 MAPKs, it is a 
natural consequence that this kinase should also be involved in a wide and diverse 
variety of functions. Indeed, roles for p38 MAPKs have been described in processes 
such as cell differentiation and migration, cell transformation, cell survival, 
inflammation, angiogenesis, myogenesis and others. Deregulation of p38 MAPK 
pathways is implicated with the development of several pathological conditions like 
rheumatoid arthritis, Alzheimer’s disease, cardiovascular dysfunction and cancer 23 
(Fig. 3). For this reason p38 MAPK comprises one of the major drug targets for 
pharmaceutical companies in today.  
 
Figure 3. Physiological roles and pathological implications of p38 MAPKs pathways. p38 
MAPKs play a central role in the regulation of many biological functions, which contribute to 
physiological processes. Deregulation of p38 MAPKs pathways lead to the development of several 
pathological conditions. Image taken from Cuenda, A. et al. 2007, Biochimica and Biophysica Acta. 
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1.3 p38α MAPK 
The p38α MAPK is the best characterized of the four p38 MAPK isoforms. Contrary 
to the other isoforms of p38 MAPK which appear to be more cell-specific, p38α 
MAPK has been found to be expressed ubiquitously in human and mouse tissues 15, 
17. In particular it is most abundant in inflammatory cells, e.g. those of myeloid origin 
15. 
 
1.3.1 p38α MAPK Signaling and Inflammation 
p38α MAPK was originally identified as a major modulator of inflammatory 
responses. It is essential in regulating the expression of cytokines in response to 
stimulation by LPS or by proinflammatory cytokines 3. It was also identified as a 
protein that binds with high affinity to a group of anti-inflammatory compounds such 
as SB202190 10,1,9,11. p38α MAPK mediates inflammatory responses partly through 
activating a gene expression programme. This activation results in the expression of 
molecules that participate in inflammation, including proinflammatory cytokines, 
chemokines and adhesion molecules. Transcriptional profiling of p38α MAPK in 
endothelial cells in response to TNF stimulation, has revealed a list of genes 
involved in inflammation that are regulated by this protein, including IL-8 60, vascular 
adhesion molecule-1 (VCAM-1) 61 and cyclooxygenase-2 (COX-2) 62, 63. In 
macrophages where p38α MAPK was deleted, stimulation with LPS also resulted in 
the downregulation of genes involved in inflammation, like IL-10, matrix 
metalloprotease 13 (MMP-13), CXC chemokine ligand 1 and 2 (CXCL1 and CXCL2) 
and again VCAM-1 28. The fact that only p38α and p38β are sensitive to inhibition by 
anti-inflammatory compounds like SB202190 and its derivates 64, 14 and knockout of 
p38β in mice did not have any effect on T-cell development, LPS-induced cytokine 
responses, rheumatoid arthritis or bowel disease progression, only served to 
highlight the importance of p38α MAPK in inflammation 5. 
 
1.3.2 p38α MAPK Knockout Mice  
Several attempts have been made to determine how p38α MAPK contributes to 
immunity and inflammation. Initially these attempts were performed with the use of 
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p38 MAPK inhibitors. Although these attempts have provided us with hints 
concerning the function of p38α MAPK in inflammation, however, they are hampered 
by the fact that p38 MAPK inhibitors have limited target specificity 65, 66. In fact, they 
have even been known to act on other kinases, e.g. JNK, when administered in 
higher concentrations 30. For this reason, the generation and use of p38α specific 
knockout mice was considered to be an important genetic tool in the elucidation of 
the role of this molecule in inflammation. Four groups have reported the generation 
of these mice 67,68,69,70. However, in all cases, loss of p38α MAPK resulted in death 
starting from embryonic day 10.5 (E10.5) and persisting for variable times 
afterwards. Insufficient vascularization during placental development was described 
as a possible cause of death. Mudget et al. found that in addition to the placental 
defect, angiogenesis was also abnormal in the yolk sac and the embryo itself 67. 
Also, Adams et al. reported massive reduction of the myocardium and malformation 
of blood vessels in the head region 68. However this defect appears to be secondary 
to insufficient oxygen and nutrient transfer across the placenta. Finally, fetuses 
surviving to relatively late stages of development are anemic and have a deficiency 
of erythropoietin (Epo) mRNA expression in their livers 69. Rescue of the placental 
defect in these mice allowed the mice to develop to term and they were normal in 
their appearance, indicating that p38α MAPK is required for placental organogenesis 
but not essential for other aspects of mammalian embryonic development 68,71. Gene 
disruption methods used to ablate p38α MAPK alleles in embryonic but not placental 
tissues 71 or at postnatal stages in a drug-inducible fashion 72 permitted survival of 
these mice. However, these p38α MAPK –null animals were found to develop 
spontaneous anomalies in homeostasis of pulmonary epithelial and fetal 
hematopoietic tissues, thus precluding further characterization of their response in 
experimentally induced diseases. 
 
1.3.3 Generation of p38α MAPK Conditional Mouse Models 
Since it was not possible to use complete p38α knockout mice to study the role of 
p38α MAPK in vivo, due to the lethality of this model and other complications 
described above, it was necessary to create a new model for this purpose. For this 
reason, our laboratory has generated a p38α MAPK mouse model where expression 
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of this protein can be controlled spatially and temporally. This was done by taking 
advantage of the Cre/loxP recombination system, which allows tissue or cell-specific 
deletion of a target gene at a given timepoint. This system is based on the specific 
activity of the bacteriophage P1-derived Cre recombinase, which recognizes and 
mediates site-specific recombination between 34 bp recognition sequences referred 
to as loxP sites. When the Cre recombinase finds two loxP sites in the same 
orientation, it deletes the sequence in between with high efficiency 73. The Cre 
recombinase can be placed under the control of cell or tissue specific promoters, 
thus allowing recombination to occur only in these specific sites. Activation of the Cre 
at a certain timepoint, i.e. an inducible Cre, has also been achieved. For example, 
the endothelial specific Cre recombinase, placed under the control of the Tie2 
promoter, was fused to a mutated estrogen receptor-ligand binding domain known as 
ERT2. This functionally inactive Cre mainly resides in the nucleus in a chaperone 
complex, which it can dissociate from and become activated in the presence of a 
ligand like tamoxifen 74. In our p38α mouse model, exons 2 and 3 that include the 
ATP-binding site of the kinase domain, are flanked by loxP sites 75.  So, in the 
presence of the Cre recombinase, these loxP flanked exons are deleted, leading to 
ablation of the protein in the given cell or tissue.  
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1.4 Atherosclerosis 
1.4.1 Atherosclerosis, a Disease of the Arteries 
Atherosclerosis is a progressive disease of the large arteries that occurs as a 
response to acute or chronic endothelial wall injury  76-78. In westernized societies, 
it is the underlying cause of about 50% of all deaths 79. The term atherosclerosis is 
derived from two Greek words –‘sclerosis’ (hardness) and ‘athere’ (gruel or 
porridge), and refers to the consistency of the lesions that are formed in this disease. 
It is characterized by lesions in the intima of the arterial wall called atheromas (also 
called atheromatous or atherosclerotic plaques) that protrude into the vascular 
lumina of the large arteries, and consist of accumulated lipids and fibrous materials 
78-80. The earliest morphologically identifiable atherosclerotic lesion is the ‘fatty 
streak’, which is made up of lipid-filled foam cells 80 but are not significantly raised 
and thus do not cause any disturbance in blood flow. In humans, they begin as 
multiple minute yellow, flat spots that can coalesce into elongated streaks, 1 cm long 
or longer (Fig. 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Fatty streak formation characterised by a collection of foam cells in the arterial intima. (A) 
Aorta with fatty streaks (arrows), associated largely with the ostia of branch vessels. (B) Photomicrograph 
of fatty streak in an experimental hypercholesterolemic rabbit, demonstrating intimal, macrophage-derived 
foam cells (arrow). (Courtesy of Dr. Myron I. Cybulsky, University of Toronto, Ontario, Canada.) 
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The fully developed, or ‘mature’ atherosclerotic plaque has a more complex 
structure, consisting of foam cells and extracellular lipid droplets in the centre of the 
plaque to form a ‘core’ region surrounded by a cap of smooth muscle cells and a 
collagen rich matrix that stabilizes it. Other cell types present in plaques include 
dendritic cells, mast cells, a few B cells and probably natural killer T cells 80 (Fig. 5).  
 
 
 
 
 
 
 
 
 
 
A 
 
 
 
 
 
Figure 5. Fully developed atherosclerotic plaque. (A) The mature atherosclerotic plaque has a core 
containing lipids and debris from dead cells. Surrounding it and stabilizing it is a fibrous cap made up of 
smooth muscle cells and collagen fibers. Image taken from Hansson, G. K. et al. 2006, Nature Reviews 
Immunology (B) Severe disease with diffuse and complicated lesions, some of which have coalesced, in 
human aorta. 
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1.4.2 Major Risk Factors of Atherosclerosis 
Atherosclerosis development is influenced by various factors, the major ones of 
which are described below: 
 
Age 
Atherosclerosis and age are intimately linked, atherosclerosis being the best 
example of an age-related disease. Although the accumulation of atherosclerotic 
plaque is typically a progressive process, it does not usually become clinically 
manifest until lesions reach a critical threshold and begin to precipitate organ injury 
in middle age or later. Thus, between ages 40 and 60, the incidence of myocardial 
infarction in men increases fivefold, even though the underlying arterial lesions were 
probably evolving before that. The prevalence of these diseases in advanced age 
has been attributed to the increase in arterial stiffness that occurs with age because 
of structural changes of the arterial walls as well as endothelial dysfunction. 
However, convincing molecular mechanisms have not yet been reported for these 
age-associated alterations of the vascular wall. Recently, the idea of vascular cellular 
senescence has become attractive as a molecular mechanism linking ageing and 
atherogenesis 81,82.  
 
Sex 
Premenopausal women are relatively protected against atherosclerosis and its 
consequences compared with age-matched men. Thus, myocardial infarction and 
other complications of atherosclerosis are uncommon in premenopausal women 
unless they are otherwise predisposed by diabetes, hyperlipidemia, or severe 
hypertension. After menopause, however, the incidence of atherosclerosis-related 
diseases increases and with greater age eventually exceeds that of men. The 
presumed protective effects of estrogens in women have been widely investigated 
with a series of large observational studies tending to support this notion 83,84. 
However, clinical trials designed to assess the effect of female hormone replacement 
have failed to report any benefit 85 or harm. Indeed, postmenopausal estrogen 
replacement probably is associated with increased cardiovascular risk and is no 
longer recommended for preventing heart disease in women 86. 
 28
 
Rozina Kardakaris                                                                                                                            p38α MAPK in Atherosclerosis                                 
Hypertension 
Hypertension is known to act on the arterial wall to promote both vascular 
remodeling, and atherosclerosis resulting in diminished arterial wall compliance and 
elevated stiffness 87. Clinical and experimental investigations have shown that 
increased blood pressure is associated with exaggerated atherosclerosis. In 
humans, measurement of carotid-artery intima-media thickness is highly correlated 
with blood pressure levels and well-reflects atherosclerosis and tracks its 
progression 88. In animal models, including rabbits 89, monkeys 90 and mouse models 
of atherosclerosis 91, it has been demonstrated that hypertension increases the rate 
of atherosclerotic plaque development. Mechanisms that could account for the effect 
of hypertension on atherosclerosis include increased endothelial permeability to LDL 
due to pressure-induced stretch 92, endothelial dysfunction 93, enhanced monocyte 
adhesion 94 and inflammation 95. 
 
Genetics 
As a complex disease process that results from the interaction between an 
individual’s genetic makeup and environmental risk factors 96-98, the genetic 
component of atherosclerosis has been elusive to characterize. Over the past three 
decades, a great deal of research has focused on defining the genetic component of 
this disease with the hopes that detailed knowledge of the genes and gene variants 
will lead to improvements in the diagnosis and treatment 99. There are rare 
Mendelian disorders in which single gene changes lead to accelerated 
atherosclerosis such as familial hypercholesterolemia. In common ‘garden variety’ 
atherosclerosis however, multiple genes probably influence the disease process by 
enhancing disease susceptibility or by modifying the impact of environmental risk 
factors. The genetic component is likely to be a collection of gene variants in the 
form of single nucleotide polymorphisms (SNPs). Each SNP individually may have a 
mild - to - moderate affect on the resulting protein by modifying the quantity, function 
or posttranslational changes. A combination of many SNPs however, may have a 
major effect. These gene variants and their resulting proteins could serve as disease 
biomarkers for diagnosis and prognosis, functional biomarkers to assess treatment 
response or as targets for novel treatment strategies. This is why much effort is 
being put into elucidating further the genetic component of atherosclerosis 99. 
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Cigarette smoking 
Cigarette smoking is a well-established risk factor in men, and an increase in the 
number of women who smoke probably accounts for the increasing incidence and 
severity of atherosclerosis in women. Prolonged smoking of one pack of cigarettes or 
more daily increases the death rate from coronary artery disease, and it appears that 
cessation of smoking does not reverse this effect 100. The precise nature for this 
effect of smoking on atherosclerosis was unclear up to now, but recently in a study 
by Wang, Z. et al., 2007 it was reported that oxidation of thiocyanate, which is 
elevated in the plasma of smokers, may lead to carbamylation of low-density 
lipoproteins (LDL) and facilitate in the progression of atherosclerosis 101. 
 
Diabetes mellitus 
Atherosclerosis is accelerated both in type 1 and type 2 diabetes. The underlying 
cause of this effect, which is common in both types of diabetes, appears to be 
hypercholesterolemia 102. Strong epidemiological evidence exists to support an 
association of glycaemic control and cardiovascular disease risk 103. Together with 
other factors like abnormal levels of blood pressure, lipids and markers of 
inflammation but also oxidative stress, it has a detrimental impact on the artery wall 
and the ability of organs to tolerate ischemic injury.  Although it has been 
demonstrated that intensive glucose control had a beneficial effect on macrovascular 
complications in type 1 diabetes patients, the effect was not the same for type 2 
patients. Therapeutic strategies that have the greatest cardiovascular benefit for 
diabetes patients appear to be those focusing on lowering of LDL-cholesterol and 
blood pressure, rather than glucose-lowering specifically 104. 
 
Lipid metabolism 
Elevated cholesterol and/or triglyceride levels in the plasma consist one of the main 
risk factors of atherosclerosis. Both these molecules are important for many different 
cellular processes. The synthesis of cellular membranes, steroid hormones and bile 
are some of the processes cholesterol is involved in. Triglycerides, which are the 
major source of energy for the body, can be used either directly or indirectly by the 
muscle and other organs or stored as fat in adipose tissues.  Transportation of 
cholesterol and triglycerides is achieved by packaging into water-soluble lipoprotein 
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particles. These lipoproteins consist of a core of apolar lipids, mainly cholesteryl 
esters and triglycerides, covered by a surface of polar molecules, primarily free 
cholesterol, phospholipids and apolipoproteins. 
Plasma lipoproteins have been divided in different classes according to their density: 
chylomicrons, very low density lipoproteins (VLDL), low density lipoproteins (LDL) 
and high density lipoproteins (HDL). Furthermore, several derivatives have been 
described, such as the chylomicron and VLDL remnants and intermediate density 
proteins (IDL). These different classes of lipoproteins not only differ in their density, 
but also in size, electrophoretic mobility, lipid content and apolipoprotein 
composition. 
Lipid metabolism can be divided into three main pathways. The exogenous pathway 
that mediates the uptake of dietary lipids by the body, the endogenous pathway that 
delivers lipids from the liver throughout the body and the reverse cholesterol pathway 
that mediates the redirection of cholesterol from the periphery to the liver 105 106 107 
108.  
Elevated levels of plasma LDL, which has an essential role in the uptake and 
transfer of lipids throughout the body, is considered to be unfavorable and 
predispose to the development of atherosclerosis. They can accumulate in the 
vascular wall where they become modified. Modifications that can occur include 
oxidation, lipolysis, proteolysis and aggregation 79. One of the modifications that is 
considered most significant especially for early lesion formation is lipid oxidation as a 
result of exposure to the oxidative waste of vascular cells. Such modifications initially 
give rise to ‘minimally oxidized’ LDL species that have proinflammatory activity but 
may not be sufficiently modified to be recognized by macrophage scavenger 
receptors. Mice lacking 12/15 lipoxygenase have considerably diminished 
atherosclerosis, suggesting that this enzyme may be an important source of reactive 
oxygen species in LDL oxidation 109.  
On the other hand, HDL also known as ‘good cholesterol’ appears to have a strongly 
protective role against atherosclerosis. The underlying cause for this protective 
mechanism is its role in the reverse cholesterol pathway, where it is involved in the 
removal of excess cholesterol from peripheral tissues. In addition, it also protects by 
inhibiting lipoprotein oxidation. This last property of HDL is due in part to the fact that 
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it carries serum paraoxonase, an esterase that can degrade certain biologically 
active oxidized phospholipids 110, 111 (Fig. 6). 
 
 
 
 
 
Figure 6. Lipid metabolism in atherosclerosis. It involves the transport of lipids, particularly cholesterol 
and triglycerides, in the blood. The intestine absorbs dietary fat and packages it into chylomicrons (large 
triglyceride-rich lipoproteins), which are transported to peripheral tissues through the blood. In muscle and 
adipose tissues, the enzyme lipoprotein lipase breaks down chylomicrons, and fatty acids enter these 
tissues. The chylomicron remnants are subsequently taken up by the liver. The liver loads lipids onto apoB 
and secretes very-low-density lipoproteins (VLDLs), which undergo lipolysis by lipoprotein lipase to form low-
density lipoproteins (LDLs). LDLs are then taken up by the liver through binding to the LDL receptor (LDLR), 
as well as through other pathways. By contrast, high-density lipoproteins (HDLs) are generated by the 
intestine and the liver through the secretion of lipid-free apoA-I. ApoA-I then recruits cholesterol from these 
organs through the actions of the transporter ABCA1, forming nascent HDLs, and this protects apoA-I from 
being rapidly degraded in the kidneys. In the peripheral tissues, nascent HDLs promote the efflux of 
cholesterol from tissues, including from macrophages, through the actions of ABCA1. Mature HDLs also 
promote this efflux but through the actions of ABCG1. (In macrophages, the nuclear receptor LXR 
upregulates the production of both ABCA1 and ABCG1.) The free (unesterified) cholesterol in nascent HDLs 
is esterified to cholesteryl ester by the enzyme lecithin cholesterol acyltransferase (LCAT), creating mature 
HDLs. The cholesterol in HDLs is returned to the liver both directly, through uptake by the receptor SR-BI, 
and indirectly, by transfer to LDLs and VLDLs through the cholesteryl ester transfer protein (CETP). The lipid 
content of HDLs is altered by the enzymes hepatic lipase and endothelial lipase and by the transfer proteins 
CETP and phospholipid transfer protein (PLTP), affecting HDL catabolism. Image taken from Rader, D. J. et. 
al., 2008, Nature. 
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1.4.3 Atherosclerosis Development and Progression 
The set of processes believed to be involved in atherogenesis and its progression 
includes the following: 
 
1) Accumulation of low density lipoprotein within the arterial intima 
The endothelium, with its tight junctional complexes, functions as a selectively 
permeable barrier between blood and tissues. Endothelial cell morphology is 
affected by physical forces such as fluid shear stress. In tubular areas of arteries 
where blood flow is uniform and laminar, endothelial cells are ellipsoid in shape and 
aligned in the direction of flow. In areas of arterial branching, where blood flow is 
disturbed, they have polygonal shapes and no particular orientation 79. In these latter 
areas, where there is predilection for lesion development 112,113, excess amounts of 
cholesterol-rich, LDL derived from plasma are deposited by passive diffusion, and 
retained in the subendothelium matrix via interactions between the LDL constituent 
apolipoprotein (apoB) and matrix proteoglycans 114.  
 
2) Migration of monocytes and T lymphocytes from the arterial blood into the 
subendothelial space and ‘fatty streak’ formation 
Once inside the arterial intima, trapped LDL undergoes modifications, including 
oxidation, lipolysis, proteolysis and aggregation 79, as described above. Such 
modifications, and in particular lipid oxidation which occurs due to reactive oxygen 
species production from endothelial cells and macrophages and has been shown to 
be significant for early lesion formation 115, can activate the endothelium. This in turn 
can express leukocyte adhesion molecules like VCAM-1. Monocytes and T-cells bind 
to VCAM-1 expressing endothelial cells and subsequently migrate into the arterial 
intima in response to locally produced chemokines like MCP-1. These monocytes 
then differentiate into macrophages in response to local macrophage-colony 
stimulating factor (M-CSF) produced by endothelial and smooth muscle cells, 
ingesting large amounts of modified LDL through the expression of scavenger 116 
receptors such as SR-A and CD36 79. This results in their conversion to ‘foam cells’ 
(macrophages with abundant lipid-filled cytoplasm). These first two processes lead 
to formation of a widely prevalent lesion, the ‘fatty streak’ 80. 
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3) Migration of smooth muscle cells from the tunica media into the affected 
area of the intima 
After formation of the ‘fatty streak’, the nascent atheroma typically evolves into a 
more complex lesion, which eventually leads to clinical manifestations.  Part of this 
process is characterized by the accumulation of smooth muscle cells in the lesion 
which occurs due to cytokine and growth factor production by the macrophages and 
T-cells in the atherosclerotic intima. Migration of smooth muscle cells can also occur 
due to other risk factors like homocysteine, which appears to injure endothelial cells 
and to stimulate proliferation of vascular smooth muscle cells 117. Once in the intima, 
they divide and synthesize and secrete all the connective tissue components of the 
plaque cap (collagen-rich connective tissue matrix, the microfibrillar component of 
elastin, proteoglycans and glycosoaminoglycans). 
 
4) Breakdown of part of the plaque connective tissue, usually at or near the 
base of the lesion to form advanced lesions 
As the lesion progresses, various factors like proteinases, collagenase, gelatinases , 
stromolysin and cathepsins are produced by the different cells types that are present 
in the atherosclerotic plaque 79. These can change the composition and vulnerability 
of the plaque by promoting the formation of a  ‘core’ or ‘pool’ which contains large 
amounts of extracellular lipid and which may be highly deformable (fibrolipid plaque). 
Besides, smooth muscle cells, macrophages and T cells, other cells that are also 
present in the plaques and can contribute to this process include dendritic cells 118, 
mast cells 119, a few B cells 120 and probably nature killer T cells. The stability of 
atherosclerotic lesions may also be influenced by infection. This may have systemic 
effects such as induction of acute phase proteins and local effects such as increased 
expression of tissue factor and decreased expression of plasminogen activator (PA), 
but also by calcification 121 and revascularization which are both common features of 
advanced lesions. 
 
5) Injury to the plaque cap that results in plaque rupture and acute thrombus 
formation 
Plaques that have become vulnerable over time may rupture an event that may be 
clinically silent and lead either to further plaque growth and hence more severe 
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stenosis of the affected arterial segment or to one of the acute syndromes of 
coronary heart disease. Inflammatory mediators appear to play a major role in 
weakening of the fibrous cap and subsequent plaque rupture. For example, the 
inflammatory mediator interferon gamma (IFN-γ) has been shown to inhibit the 
synthesis of interstitial collagen, a product of smooth muscle cells in the artery wall 
that lends strength to the ‘fibrous cap’. Also, various proteases produced by 
macrophages, like interstitial collagenases, gelatinases and stromolysin, can 
participate in matrix degradation 122. 
 
 
 
                                
 
Figure 7. The stages of atherosclerotic lesion formation and progression. Image taken from Lusis, 
A. J. et al., 2004, Annual Review of Genomics and Human Genetics. 
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1.4.4 Inflammation and Atherosclerosis 
95 years ago, Nikolaj N. Anitschkov and Semen S. Chalatov performed the first 
important experiment in atherosclerosis research. They speculated that the 
cholesterol deposit in the atherosclerotic lesion is caused by the consumption of fat 
and tested this hypothesis by feeding rabbits cholesterol. In their classical 1913 
paper, they demonstrated that this was the case; cholesterol leads to 
atherosclerosis. This finding established the link between diet, metabolism, and 
atherosclerotic and cardiovascular disease and would set the stage for much of 
cardiovascular research for the rest of the 20th century. Anitschkov recognized, as 
Virchow before him, that the atherosclerotic plaque contains not only lipids but also 
several types of cells, among them inflammatory cells. Antischov identified them as 
smooth muscle cells, macrophages, and lymphocytes.  While this discovery of 
cholesterol as an etiologic agent became historic, his observation of macrophages 
and lymphocytes in the lesion was forgotten 123.  
Today, atherosclerosis is considered to be an inflammatory disease, characterized 
by the accumulation of a large number of immune cells in the atherosclerotic lesion, 
in particular macrophages and T-cells which form the first lesions of atherosclerosis 
since they are recruited to the arterial intima through chemokines and adhesion 
molecules expressed on the endothelium 124. As our knowledge of this disease 
increases, the understanding that immune responses are involved in atherosclerosis 
development from the initiation through to its thrombotic complications becomes 
more and more established. This realization is clinically useful because, therapeutic 
agents can be redirected from lipid lowering, to targeting inflammatory responses. 
Statins, which have shown striking clinical benefit against atherosclerosis during the 
past decade, were initially thought to have these effects by lowering cholesterol 
concentrations in the blood. However, recent data indicate that part of the clinical 
benefit occurs because of an anti-inflammatory effect that is not related to LDL 
reduction 80. Therefore, directing future studies in atherosclerosis on the 
inflammatory component of this disease appears to be the way forward in its 
treatment. 
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1.5 Aim of the Thesis 
The aim of this project was to study the macrophage and endothelial-specific role of 
p38α MAPK in atherosclerosis development, two of the most important cell types 
involved in the initiation and progression of this disease. At the same time, we 
wanted to generate two new p38α MAPK mouse models, p38αCA (Constitutively 
Active) and p38αKD (Kinase Dead), to potentially assist us in our studies, but that 
could also be used as genetic tools to answer other interesting questions in relation 
to the function of this molecule. 
 
1.5.1 Investigation of the Macrophage and Endothelial-Specific Role 
of p38α MAPK in Atherosclerosis 
As describe above, inflammation plays a key role in the development and 
progression of atherosclerosis. Inflammatory triggers include oxidized lipoproteins 
(oxLDL), hypertension and diabetes. As a molecule involved in inflammation, various 
roles have been attributed to p38α MAPK with respect to atherogenesis, including 
the regulation of scavenger receptor expression like CD36 in macrophages and 
therefore oxLDL uptake 125 and regulation of expression of the monocytic chemokine 
receptor CXCR2 that is upregulated in response to oxLDL 126. It has been described 
as a mediator of vascular smooth muscle cell migration by stimulating vascular 
endothelial growth factor (VEGF) in response to thrombin-induced ROS production 
127. In endothelial cells, it has been associated with migration and proliferation 128, 129, 
130, cell permeability 131, apoptosis 132 and adhesion molecule expression, like 
VCAM-1 61, 63. Finally, it is critical for the production and activity of multiple pro-
inflammatory cytokines like TNFα, IL-1β, IL-6 and IL-8 in most of the cell types that 
participate in atherosclerosis development 133, 134, 135, 136, 28.  
Due to this suggestive in vitro evidence that p38α MAPK is involved in 
atherosclerosis development, here we wanted to address the cell-specific in vivo role 
of p38α MAPK signalling in vascular endothelial cells and macrophages. These cell 
types were selected because of their significant role in the development and 
progression of this disease. As a reminder, endothelial cells (ECs) are involved in all 
stages of atherogenesis and their dysfunction is a key early event in plaque 
formation. The strategic location of the endothelium between blood and tissue and 
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the constitutive properties of endothelial cells, allow them to monitor the transport of 
plasma molecules, by employing bidirectional receptor-mediated and receptor-
independent transcytosis and endocytosis, and to regulate vascular tone, cellular 
cholesterol and lipid homeostasis. Heterogeneity of ECs defines lesion-prone areas 
of increased shear stress 137. Similarly, monocytes/ macrophages play a key role 
both in initation and progression of atherosclerosis. They function as a scavenger 
cell, an immune mediator cell, and a source of chemotactic molecules and cytokines. 
Recruitment of monocytes, as described earlier is one of the earliest events in 
atherosclerosis. In the intima, monocytes develop into macrophages, which are 
important mediators of inflammation and the innate (antigen-independent) immune 
response in atherosclerosis. Macrophages contribute to the local inflammatory 
responses through production of cytokines, free radicals, proteases, and 
complement factors. By serving as antigen-presenting cells, macrophages 
participate in the acquired immune response. The uptake of modified lipoproteins by 
macrophages leads to the accumulation of cholesterol esters and formation of 
macrophage-derived foam cells, the hallmark of the fatty streak. Macrophages also 
contribute to lesion remodeling and to plaque rupture by secreting matrix 
metalloproteinases. Thus macrophages contribute to the evolution of atherosclerosis 
in diverse and significant ways 138. 
For this study, we made use of the conditional p38α MAPK mouse model previously 
generated in our laboratory. Crossing these mice with myeloid (LysMCre) and 
endothelial (Tie2-CreERT2) specific Cre lines allowed us to generate mice with 
macrophage (p38αMY-KO) and endothelial (p38αEC-KO) specific deficiency of this 
protein. The well established Apolipoprotein E deficient mouse model of 
atherosclerosis 139, was then further crossed with these mice, to render them 
susceptible to atherosclerosis development. 
 
1.5.2 Generation of Two New p38α MAPK Mouse Models: p38αCA 
and p38αKD 
Besides studying the function of p38α MAPK in atherosclerosis by knocking out the 
protein in macrophages and endothelial cells, we also wanted to create two new 
models p38αCA and p38αKD, a constitutively active and kinase dead form of the 
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protein, respectively. These mice are very important, each in a different manner, 
because they can help better understand the role of p38α MAPK both in 
atherosclerosis, but also in other pathological processes this protein may be related 
to. 
Previous efforts to obtain active forms of MAPKs have only been partially successful. 
Several gain-of function mutations that were identified in the S. cerevisiae FUS3 140, 
141 and in the Rolled MAPK of Drosophila melanogaster  142, 143 did not render 
kinases catalytically active. Also, the use of MAPKK-MAPK hybrids 144, 145, i.e. 
coupling of MAPKs with their upstream kinases which seemed a more useful 
approach, did not work in vivo, since these two molecules are not colocalized in the 
cell and are differently controlled. The most successful attempts have been with 
producing constitutively active upstream kinases, like MKK3 and MKK6 for p38α 
MAPK. However this system does not allow the isolation of one molecule and its 
downstream targets, since it activates more than one downstream kinases. 
Therefore, the generation of a mouse model where only p38α MAPK would be 
constitutively activated would be very useful in isolating and examining further the 
components of this specific pathway. In this study we proceeded in the generation of 
these mice, by taking advantage of three point mutations described previously for the 
p38 homologous yeast protein, Hog1, that render this protein catalytically and 
biologically hyperactive 146. 
On the other hand, the p38αKD model, which was generated in this study by 
introducing a mutation in the ATP-binding site of the kinase domain in exon 2 
rendering the protein catalytically and biologically inactive, is a useful model because 
it can assist our studies with this molecule by excluding the possibility of 
compensation that can occur by other isoforms of p38 when knocking out p38α. It is 
also a more accurate model to prove or disprove studies carried out with small 
molecule pharmacological inhibitors, since these molecules act by inhibiting the 
catalytic activity of the protein. Finally, it will allow the elucidation of any kinase-
independent function of p38α MAPK. 
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2. Results 
2.1 Macrophage and Endothelial-Cell Specific Role of p38α 
MAPK in Atherosclerosis 
2.1.1 Macrophage-Cell Specific Role of p38α MAPK in 
Atherosclerosis 
2.1.1.1 Generation of Myeloid-Specific p38α Knockout Mice in an ApoE 
Deficient Background 
In order to address the macrophage-specific in vivo role of p38α MAPK in 
atherosclerosis we generated mice with specific ablation of p38α in myeloid cells by 
crossing mice with loxP-flanked p38α alleles  (p38αFL/FL), previously generated in our 
laboratory 75, with LysMCre mice, expressing Cre under the myeloid-specific M 
lysozyme promoter (p38αMY-KO)147 (Fig. 8). p38αMY-KO mice were then bred into the 
ApoE-/- genetic background, a mouse model that spontaneously develops 
atherosclerotic plaques due to elevated levels of cholesterol circulation 148,  
rendering the mice prone to atherosclerosis.  
 
 
 
 
 
 
 
 
Figure 8. Strategy for the generation of myeloid–specific p38α MAPK knockout mice. Myeloid-
specific knockout mice were generated by crossing p38αFL/FL mice with LysMCre mice. 
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2.1.1.2 Efficient Ablation of p38α MAPK in Macrophages of p38αMY-KO/ ApoE-/- 
Mice 
Immunoblot and southern blot analysis of bone-marrow derived macrophage 
(BMDM) extracts showed efficient ablation of p38α MAPK in macrophages of 
p38αMY-KO mice (Fig. 9A and B, respectively). LPS stimulation (1μg/ml) induced p38α 
MAPK activation in wild-type cells (ApoE-/- in our case)28, which, as expected, was 
clearly reduced in p38αMY-KO/ApoE-/- mice (Fig. 9B).  
 
 
 
 A 
 
 
 
 
 
 B 
 
 
 
 
 
 
 
 Figure 9. Deletion efficiency of p38α MAPK in macrophages of p38αMY-KO mice. 
 
 
(A) Analysis of deletion efficiency of p38α MAPK in macrophages by isolation of BMDMs from p38αMY-
KO and p38αFL/FL mice and southern blotting to detect the deleted p38α allele after cre recombination. 
p38αMY-KO mice, n= 3; p38αFL/FL n= 3. (B) LPS (1μg/ml, Sigma) stimulation of BMDMs from p38αMY-KO 
and p38αFL/FL mice showed a clear reduction in total p38 activation (total p-p38) and ablation p38α 
MAPK. 
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2.1.1.3 p38α MAPK Ablation Did not Affect in vitro Lipid Uptake and Foam Cell 
Formation  
Given the extensive literature claiming important functions for p38α MAPK in 
macrophages with respect to atherosclerosis as a result of studies with p38-specific 
inhibitors 125, 126, and in an attempt to investigate these claims in a more 
physiological environment without the use of inhibitors, we isolated and cultured 
thioglycolate-elicited peritoneal macrophages from p38αMY-KO/ApoE-/- and ApoE-/- 
mice. These macrophages were then stimulated with 50µg/ml oxLDL and uptake 
was compared in p38αMY-KO/ApoE -/- and ApoE-/- macrophages by FACS analysis 
(Fig. 10B). Our results showed that there was no significant difference in the uptake 
of modified lipids.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Similar oxLDL uptake in macrophages of p38αMY-KO/ ApoE -/- and ApoE -/- mice 
stimulated in vitro with oxLDL, (A) Staining of oxLDL stimulated macrophages with Oil red O (lipid 
staining). Foam cells, which are defined as cells with ≥ 10 lipid droplets, are indicated with arrows. (B) 
Quantification of oxLDL uptake by thioglycolate-elicited peritoneal macrophages after stimulation with 
50µg/ml oxLDL for 2.5 hrs. OxLDL was previously labeled with DiI and quantification was performed 
by FACS analysis. Error bars represent SD. ApoE -/- mice, n= 3; p38αMY-KO/ ApoE -/- n= 3. 
B 
A 
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However, we did observe a considerable reduction in the expression of the 
chemokine MIP-2α and the cytokine IL-1β (Fig. 11B, top and bottom respectively), 
which was previously reported upon LPS stimulation in p38αMY-KO macrophages 28.  
 
 
 A 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Considerable reduction in MIP-2α and IL-1β in p38αMY-KO/ ApoE-/- macrophages 
stimulated with oxLDL in vitro Relative mRNA expression levels of chemokine MIP-2α (A) and 
cytokine IL-1β (B) in macrophages isolated from p38αMY-KO/ ApoE-/-  and ApoE -/-  mice stimulated with  
50µg/ml oxidized LDL for 2.5 hrs.Error bars represent SD. ApoE -/-   mice, n= 7; p38αMY-KO/ ApoE -/- , n= 
9. 
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2.1.1.4 p38α MAPK Ablation in Macrophages Did not Affect Atherosclerosis 
Development in vivo 
From our in vitro studies in p38α MAPK knockout macrophages it was apparent that, 
surprisingly and contrary to previous claims, p38α MAPK ablation did not affect 
oxLDL uptake by macrophages. In order to address the role of p38α in macrophages 
in the pathogenesis of atherosclerosis in vivo, we placed groups of male and female 
p38αMY-KO/ApoE-/- and their ApoE-/- littermates on a cholesterol-rich ‘western diet’ for 
10 weeks starting from 6-8 weeks of age. Analysis of bodyweight and cholesterol 
levels before and after the ‘western diet’ revealed no differences between the two 
genotypes, although at week 10 cholesterol levels had increased ∼ 5-fold in both 
male and female littermates and both had gained ∼ 5gr of weight (Fig. 12).  
 
 
A 
 
 
 
 
 B 
 
 
 
 
 Figure 12. Bodyweight and cholesterol levels of p38α
MY-KO/ApoE-/- mice. (A) Cholesterol (mg/dl) 
and (B) bodyweight (gr) levels of male and female mice before and after 10 weeks of a cholesterol-rich 
‘western’ diet starting from 6-8 weeks. p38αMY-KO/ ApoE -/- males, n= 9; ApoE-/- males, n= 15; p38αMY-
KO/ ApoE -/-  females, n= 8; ApoE-/- females, n= 9. Error bars represent SD. 
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After 10 weeks on a western diet, mice were sacrificed, and atherosclerotic lesion 
development was assessed in the whole aorta by en face Sudan IV staining (Fig. 
13), but also at the aortic sinus by histological analysis of consecutive sections 
followed by cross-sectional plaque area quantification (Fig. 14). This analysis did not 
reveal any differences in lesion size between male and female p38αMY-KO/ApoE-/- and 
their ApoE-/- littermates, either in the whole aorta or in the aortic sinuses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 13. Deficiency of p38α MAPK in macrophages does not affect lesion development in the 
aorta of p38αMY-KO/ApoE-/- mice. Quantification of atherosclerotic plaque size on whole aorta from 
male p38αMY-KO/ ApoE-/- and ApoE-/- mice. En face Sudan IV staining of lesions. Scale bar 2 mm. 
p38αMY-KO/ ApoE -/- males, n= 9; ApoE-/- males, n= 15. Error bars represent SD. 
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Figure 14. Deficiency of p38α MAPK in macrophages does not affect atherosclerosis development 
at the aortic sinus of p38αMY-KO/ApoE-/- mice. Quantification of the lesion area of atherosclerotic plaques 
at the aortic sinus of p38αMY-KO/ApoE-/- and ApoE-/- female (A) and male (B) mice. Plaques are marked by 
arrows on aortal cross sections at the height of the aortic sinus. p38αMY-KO/ApoE-/- males, n= 9; ApoE-/- 
males, n= 15; p38αMY-KO/ApoE-/- females, n= 8; ApoE-/- females, n= 9. Error bars represent SD.Scale bar, 
0.2 mm. 
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To further characterize the lesions at the aortic sinus in these mice, we stained and 
quantified collagen content (Fig. 15A), foam cell content (Fig. 15B) and necrotic core 
formation (Fig. 15C), since it had previously been observed that atherosclerotic 
lesions in p38αMY-KO/ApoE-/- mice appear to be more advanced compared to ApoE-/- 
mice even though plaque size is not altered. More specifically, these mice were 
characterized by increased lesional necrosis and decreased collagen content 
compared to ApoE-/- mice 149. However, in our case, this analysis did not reveal any 
differences either in collagen content (Fig. 15A) or lesional necrosis (Fig. 15C), after 
quantification at the aortic sinus. We also did not observe any differences in foam 
cell content (Fig. 15B), between the two genotypes. Finally, p38α MAPK has been 
shown to regulate the expression of many genes involved in the initiation and 
progression of atherosclerotic lesions, including cytokines like TNF and IL-6, 
chemokines like IL-8 and adhesion molecules like VCAM-1 and ICAM-17,61,70,150,151, 
an effect thought to be mediated via a mechanism involving messenger RNA 
turnover and protein translation3,61. Thus, we tested with real-time PCR (qRT-PCR) 
the expression of a panel of cytokines chemokines and adhesion molecules on RNA 
isolated from the aortic arch of p38αMY-KO/ApoE-/- and their ApoE-/- littermates after 10 
weeks on a ‘western’ diet. Although we observed a slight upregulation in most of the 
genes tested, there were no statistically significant differences in any of these genes 
(Fig. 16). Thus, we can conclude that p38α MAPK signaling in macrophages does 
not play a significant role in the development of atherosclerosis, in the ApoE deficient 
mouse model. 
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Figure 15. Similar plaque characteristics in p38αMY-KO/ ApoE-/- and ApoE-/- mice   
(A) Quantification of collagen content (Masson Trichrome staining) at the aortic sinus of p38αMY-KO/ 
ApoE-/- and ApoE-/- mice. Collagen fibers (blue) indicated by arrows. p38αMY-KO/ ApoE-/-  females, n= 6; 
ApoE-/- females, n= 6. (B) Quantification of foam cell content (MOMA2 staining) at the aortic sinus of 
p38αMY-KO/ ApoE-/- and ApoE-/- mice. Foam cells (red) indicated by arrows. p38αMY-KO/ ApoE-/- females, 
n= 6; ApoE-/- females, n= 6. (C) Quantification of necrotic core formation at the aortic sinus of p38αMY-
KO/ ApoE-/- and ApoE-/- mice  (nec=necrosis). p38αMY-KO/ ApoE-/- females, n= 8; ApoE-/- females, n= 9. 
Error bars represent SD. 
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Figure 16. Similar mRNA expression of proinflammatory cytokines, chemokines and adhesion 
molecules in p38αMY-KO/ ApoE-/- and ApoE-/- mice. Relative mRNA levels of adhesion molecules (A), 
proinflammatory cytokines (B) and chemokines (C) in aortal arches from p38αMY-KO/ApoE-/- and ApoE-/- mice 
after 10 weeks on a cholesterol rich ‘western’ diet. p38αMY-KO/ApoE-/- females, n= 8; ApoE-/- females, n= 
9.Error bars represent SD. 
C A B 
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2.1.2 Endothelial-Cell Specific Role of p38α MAPK in 
Atherosclerosis 
2.1.2.1 Generation of Endothelial-Specific p38α Knockout Mice in an ApoE 
Deficient Background 
In order to address the endothelial-specific in vivo role of p38α MAPK in 
atherosclerosis, we generated mice with specific ablation of p38α in endothelial 
cells, in the ApoE-deficient genetic background (p38αEC-KO/ ApoE-/-). This was 
accomplished by crossing p38αFL/FL mice with mice expressing a tamoxifen-inducible 
Cre transgene fused to a mutated estrogen receptor ligand-binding domain known as 
ERT2 (Tie2CreERT2) (Fig. 17). Expression of Cre in this form is inactive and only 
becomes active upon treatment with tamoxifen 74. 
 
Endothelial cells 
(Tie2-CreERT2)
Other cells
 
 
 
 
 
 
 
 
 
 Figure 17. Strategy for the generation of endothelial–specific p38α MAPK knockout mice. 
Endothelial-specific knockout mice were generated by crossing p38αFL/FL mice with Tie2CreERT2 mice. 
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2.1.2.2 Efficient Ablation and Diminished Activation of p38α MAPK in 
Endothelial Cells of p38αEC-KO/ ApoE-/- Mice 
To assess the efficiency of p38α MAPK ablation we measured expression of this 
protein in primary lung endothelial cells by immunoblotting. Primary lung endothelial 
cells were isolated from dissociated lung tissue isolated from groups of 6-8 week old 
p38αEC-KO/ApoE-/- and their p38αFL/FL/ApoE-/- littermates that did not carry the Tie2-
CreERT2 transgene. These mice had previously been fed a tamoxifen containing diet 
(400mg/kg tamoxifen citrate, 5% sucrose in phytoestrogen-free chow) for 5 
consecutive weeks to induce Cre-mediated excision of the p38α loxP-flanked allele 
in endothelial cells 152, followed by 10 weeks on a cholesterol rich ‘western diet’ to 
promote atherosclerosis development. MACS (Magnetic Cell Sorting) was used to 
enrich the CD146+ endothelial cell fraction. Immunoblot analysis of protein lysates 
from whole lung, CD146+ and CD146- cell fractions showed efficient ablation of p38α 
MAPK in endothelial cell isolates from p38αEC-KO/ApoE-/- mice taken at the end of the 
10 week period of ‘western diet’ feeding (Fig. 18). In order to study p38α MAPK 
activation in endothelial cells with p38α deficiency, we isolated lung primary 
endothelial cells from p38αFL/FL/ApoE-/- mice and used His-TAT-NLS-Cre (HTNC), a 
transducible Cre recombinase that can be used efficiently to mediate recombination 
of loxP flanked alleles in cultured cells 153,154, to induce cre recombination and thus 
p38α deletion in these cells. As can be seen from figure 19B, immunobloting for 
p38α in endothelial cells after HTNC treatment, showed efficient ablation of this 
protein. Stimulation of lung endothelial cells in vitro with 100µg/ml oxLDL, treated 
(+HTNC) or untreated (-HTNC) with HTNC, showed very low levels of total p38 
activation in cells positive for Cre recombination compared to wild-type (untreated) 
cells (Fig. 19B). Purity of endothelial cell cultures was assessed by FACS analysis 
after staining with CD146 (Fig. 19A). Taken together, these results indicate that the 
mouse models generated were sufficient for the purpose of this study. 
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Figure 18. Deletion efficiency of p38α MAPK in primary lung endothelial cells after 10 weeks of a 
cholesterol rich ‘western diet’. Analysis of deletion efficiency in endothelial-specific knockout mice after 5 
weeks of a tamoxifen diet and 10 weeks of a cholesterol-rich ‘western diet’ by MACS sorting with the mouse 
endothelial cell marker CD146. FACS analysis of lung cell suspensions showed efficient separation of 
CD146+ (positive) and CD146- (negative) fractions, whereas immmunoblotting of cell extracts from each 
sorting step showed efficient ablation of p38α in p38αEC-KO/ApoE -/- mice compared to ApoE -/- mice. p38EC-
KO/ApoE-/- females, n= 9; ApoE-/- females, n= 6. 
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Figure 19. Efficient ablation of p38α MAPK and total p38 activation in HTNC treated 
p38αFL/FL/ApoE-/- endothelial cells, in vitro. (A) FACS analysis of primary lung endothelial cells to 
check for purity of population, after treatment with HTNC for 16hrs at passage 8. Both HTNC treated and 
untreated populations showed ∼70% purity for endothelial cells, when stained with the mouse 
endothelial cell marker CD146.(B) Immunoblotting for p38α and total p-p38 on lung endothelial extracts 
after stimulation with 100μg/ml oxLDL for the indicated timepoints showed strong reduction in total p38 
activation and p38α expression. Cells were isolated from the lung of p38αFL/FL/ApoE-/- mice and either 
treated or not treated with HTNC for 16hrs to induce cre recombination of p38α. Cells were passaged 
twice before stimulation. 
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2.1.2.3 In vitro Stimulation of Lung Primary Endothelial Cells with OxLDL 
Showed a Clear Reduction in Adhesion Molecule and Chemokine Expression 
in the Absence of p38α MAPK 
In order to study the effect of p38α MAPK in endothelial cells with respect to 
atherosclerosis, we isolated primary lung endothelial cells from p38αFL/FL/ApoE-/- and 
treated them with HTNC as described above, to induce cre recombination of the 
p38α loxP flanked alleles. After assessing the purity and p38α ablation of these in 
vitro cultures (Fig.19A and B, respectively), we stimulated these cells with oxLDL 
(100µg/ml) for various timepoints, up to 48hrs. We then examined the expression of 
various chemokines and adhesion molecules that are implicated in atherosclerosis 
development, and have been previously reported to be regulated, at least partly, by 
p38. qRT-PCR for the adhesion molecule VCAM-1, but also the chemokines IP-10, 
MCP-1 and Gro-KC, which are all involved in the recruitment and uptake of 
monocytes into the arterial intima, showed a statistically significant reduction for all 
these molecules, in response to oxLDL (Fig 20). These results indicated an 
atherogenic role for p38α MAPK, and therefore we hypothesized that ablation of 
p38α in the endothelium would lead to a significant reduction in atherosclerosis 
development, compared to wild-type (ApoE-/-) mice. 
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Figure 20. Downregulation of adhesion molecules and cytokines in oxLDL stimulated p38α MAPK 
knockout endothelial cells, in vitro.Relative mRNA expression levels of adhesion molecule VCAM-1 
and chemokines IP-10, MCP-1 and Gro-KC in HTNC treated or untreated primary lung endothelial cells 
isolated from p38αFL/FL/ ApoE-/-  and ApoE -/-  mice stimulated with 100µg/ml oxLDL for the indicated 
timepoints. 
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2.1.2.4 In vitro Stimulation of Lung Endothelial Cells Showed a Clear Reduction 
in JNK Signaling in the Absence of p38α MAPK 
Since it has been previously shown that ablation of p38α MAPK in many cell types, 
including macrophages 28, 75, can lead to increased activation of JNK, we decided to 
also examine the effect on JNK activation when removing p38α MAPK from 
endothelial cells. This was a concern for us since JNK has also been implicated in 
atherosclerosis development 155, and its hyperactivation in the absence of MAPK 
could counterbalance the effect of p38α MAPK ablation. For this reason we 
stimulated primary lung endothelial cells with oxLDL and examined the 
phosphorylation of JNK. Immunoblotting for p-JNK showed decreased activation in 
cells where p38α MAPK had been deleted with prior HTNC treatment (Fig. 21).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Decreased JNK phosphorylation upon oxLDL stimulation in primary lung endothelial 
cells, in the absence of p38α MAPK. Immunoblotting with p-JNK on whole cell extracts obtained 
from p38FL/FL/ApoE-/- primary lung endothelial that had been pre-treated with HTNC to delete p38α 
MAPK and stimulated with 100µg/ml oxLDL for the indicated timepoints. Cells not treated with HTNC 
used as wild-type. 
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2.1.2.5 p38α MAPK Ablation in Vascular Endothelial Cells Does not Affect 
Atherosclerosis Development or Progression  
In order to study the effect of endothelial-specific p38α MAPK ablation on the 
development of atherosclerosis, we placed groups of male and female p38αEC-
KO/ApoE-/- and their ApoE-/- littermates on a tamoxifen based diet for 5 weeks to 
induce Cre-mediated excision of the loxP-flanked p38α allele in endothelial cells. 
This was then followed by a cholesterol-rich ‘western’ diet for 10 weeks. Analysis of 
cholesterol levels before and after the ‘western’ diet revealed no differences between 
the two genotypes, although at week 10 cholesterol levels had increased ∼ 3-fold in 
both male and female littermates (Fig. 22A). Bodyweight increased about 5 gr for 
males and 10 gr for females on average after 10 weeks of a ‘western diet’ (Fig. 22B).  
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Figure 22. Bodyweight and cholesterol levels of p38α
A 
B 
EC-KO/ApoE-/- mice after 10 weeks of a 
cholesterol rich ‘western’ diet. (A) Cholesterol (mg/dl) and (B) weight (gr) levels of male and female 
p38αEC-KO/ApoE-/- and ApoE-/- mice before and after 10 weeks of a cholesterol-rich ‘western diet’ 
(previously fed a tamoxifen diet for 5 weeks to induce cre expression). p38αEC-KO/ApoE-/- males, n= 14; 
ApoE-/- males, n= 15; p38αEC-KO/ApoE-/- females, n= 14; ApoE-/- females, n= 13. Error bars represent 
SD. 
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After 10 weeks on the ‘western diet’, mice were sacrificed and atherosclerotic lesion 
development was assessed in the whole aorta by en face Sudan IV staining (Fig. 
23), but also at the aortic sinus by histological analysis of consecutive sections 
followed by cross-sectional plaque area quantification (Fig. 24). This analysis did not 
reveal any differences in lesion size between male and female p38αEC-KO/ApoE-/- and 
ApoE-/- littermates, either in the whole aorta or in the aortic sinuses.  
 
 
ApoE -/-  p38α
EC-KO/ApoE -/-  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Deficiency of p38α MAPK in endothelial cells does not affect lesion development in 
the aorta of p38αEC-KO/ApoE -/- mice. Quantification of atherosclerotic plaque size on whole aorta from 
female p38αEC-KO/ApoE-/- and ApoE-/- mice. En face Sudan IV staining of plaques. p38αEC-KO/ApoE-/- 
females, n= 14; ApoE-/- females, n= 13. Error bars represent SD.Scale bar, 2 mm  
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Figure 24. Development of atherosclerotic lesions in the aortic sinus of p38αEC-KO/ApoE-/- mice. 
Quantification of lesion area on atherosclerotic plaques at the aortic sinus of p38αEC-KO/ApoE -/- and ApoE -/- 
female (top) and male (bottom) mice. Plaques are marked by arrows on aortal cross sections at the height 
of the aortic sinus. p38αEC-KO/ ApoE-/- males, n= 14; ApoE-/- males, n= 15; p38αEC-KO/ ApoE-/- females, n= 
14; ApoE-/- females, n= 13. Scale bar, 0.2 mm 
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QRT-PCR analysis on cDNA from the aortic roots of these mice did not show any 
significant differences in cytokine, chemokine or adhesion molecule expression (Fig. 
25). 
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Figure 25. Similar mRNA expression of proinflammatory cytokines, chemokines and adhesion 
molecules in p38αEC-KO/ApoE-/- and ApoE-/- mice 
Relative mRNA levels of adhesion molecules (A), chemokines (B) and proinflammatory cytokines (C) 
of aortal arches from p38αEC-KO/ApoE-/- and ApoE-/- mice after 10 weeks on western diet. p38αEC-
KO/ApoE-/- females, n= 9; ApoE -/-  females, n = 6.Error bars represent SD. 
 
B A C 
 
To further characterize the progression of atherosclerotic lesions at the aortic sinus 
in these mice, we quantified collagen content (Fig. 26A), foam cell content (Fig. 26B) 
and necrotic core formation (Fig. 26C). This analysis showed that atherosclerotic 
plaques in p38αEC-KO/ApoE-/- and their ApoE-/- littermates both developed at similar 
rates with neither of the genotypes showing more or less advanced lesions. So, from 
these results, and contrary to what we hypothesized based on our in vitro 
experiments, we can conclude that specific ablation of p38α MAPK in vivo does not 
affect the development and progression of atherosclerosis in the ApoE-/- mouse 
model. 
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Figure 26. Similar lesion characteristics in atherosclerotic plaques of p38αEC-KO/ApoE-/- and ApoE 
-/- mice. (A) Quantification of collagen content (Masson Trichrome staining) at the aortic sinus of p38αEC-
KO/ApoE-/- and ApoE-/- mice. Collagen fibers (blue) indicated by arrows. p38αEC-KO/ApoE-/- females, n= 9; 
ApoE-/- females, n = 6. (B) Quantification of foam cell content (MOMA2 staining) at the aortic sinus of 
p38αEC-KO/ApoE-/- and ApoE-/- mice. Foam cells (red) indicated by arrows. p38αEC-KO/Apo-/- females, n= 9; 
ApoE-/-  females, n = 6. (C) Quantification of necrotic core formation at the aortic sinus of p38αEC-
KO/ApoE-/- mice (nec=necrosis). p38αEC-KO/ApoE -/- females, n= 9; ApoE-/- females, n = 6. Error bars 
represent SD. 
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2.2 Generation of p38αCA (Constitutively Active) and 
p38αKD (Kinase Dead) Mice 
2.2.1 Generation of p38αCA (Constitutively Active) Mice 
In order to produce knock-in mice expressing a constitutively active form of p38α 
MAPK we generated mutant forms of this kinase, by inserting point-mutations into 
the mouse p38α cDNA, based on a recent study involving the homologous yeast 
protein Hog1. In this study random mutagenesis of the Hog1 gene generated 
hyperactive forms of this protein 146. Combination of these mutations gave mutants 
with a 70-100 fold increase in activity 156. The most active form of p38α MAPK was 
used to generate the constitutively active mice by taking advantage of the ROSA26 
targeting vector that allows the insertion of a transgene into the ROSA26 locus and 
its ubiquitous expression. 
 
2.2.1.1 DpnI Mutagenesis of the Mouse p38α MAPK cDNA to Generate 
Hyperactive Mutants 
The mouse p38α MAPK (MAPK14) cDNA, obtained from the laboratory of Roger 
Davies (pCMV5-p38α vector), was PCR-amplified with primers containing BamHI 
restriction sites (see methods), and subcloned into the pGEX-2T vector (Appendix 
IV), which is a GST gene fusion vector that can be used for inducible, high-level 
intracellular expression of genes as fusions with glutathione S-transferase. Five 
different mutants of p38α MAPK were generated using DpnI (endonuclease specific 
for methylated DNA) mutagenesis and the pGEX-2T/p38α plasmid as a template, 
based on the previously published hyperactive mutants of the homologous Hog1 
yeast protein. From these, three were single point mutations (Table 1) and two were 
double mutants generated by combining the mutations listed in table 1, 
D176A/F327L and D176A/Y323L. The mutant plasmids generated from DpnI 
mutagenesis were transformed into DH5α E. coli cells and plated on 10 cm3 agar 
plates containing ampicillin (100µg/ml). DNA minipreps were prepared from six 
colonies, for each mutation, and sequencing allowed us to identify the clones where 
the correct mutations had been inserted (Fig. 27) 
 62
 
Rozina Kardakaris                                                                                                                            p38α MAPK in Atherosclerosis                                 
 
Mutation Structure domain Comments 
D176A Close to Thr174 
phosphoacceptor  
 
Conserved residue in human, 
mouse and yeast  
 
Y323L Conserved L16 domain  
 
Phe318 in yeast. Mutant 
exhibited highest activity 
F327L Conserved L16 domain  
 
Phe322 in yeast. 70-fold activity 
in human p38  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. Sequencing of p38α MAPK mutants generated by DpnI mutagenesis. In this figure, 
sequencing of the D176A mutant is depicted as an example. From the four different clones sequenced, 
only clone three was positive for the mutation. Alignment with the p38α MAPK cDNA was performed 
using the program ‘BioEdit’, which is freely available online. 
Table 1. Point mutations that hyperactivate the p38α MAPK yeast homologue, Hog1. 
The point mutations listed in the table were selected based on previous random mutagenesis studies 
with the yeast homologue of p38α MAPK, Hog1. These mutations resulted in hyperactivation of the 
Hog1 protein. 
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2.2.1.2 p38α MAPK Mutant GST-Purification from DH5α E.coli Cells  
Once the clones with the correct point mutations in the p38α MAPK cDNA had been 
identified, all mutants were overexpressed in DH5α cells by adding 1mM IPTG to 
induce the lac promoter present in the pGEX-2T vector, and allowing the cells to 
grow at 37˚C for ∼ 3hrs until they had reached an O.D. of ∼ 0.6-0-7. After 3hrs, cells 
were centrifuged 10 mins/5000 rpm, the pellets were collected and GST-purification 
of the p38α MAPK, p38α MAPK mutants and ATF2 (substrate for p38α MAPK) was 
performed as described in the methods. Elution of the proteins fused to GST was 
performed with 5x500μl 15mM glutathione (Fig. 28). Samples containing the eluted 
protein were pooled. As can be seen in the figure, a large amount of the desired 
GST-tagged protein was lost in the pellet during the clearspin. However, there was 
still enough protein eluted to carry out kinase assays and examine the activity of the 
p38α MAPK mutants generated. 
 
La
dd
er
 
C
le
ar
sp
in
 
Su
pe
rn
at
an
t 
El
ut
io
n 
1 
El
ut
io
n 
2 
El
ut
io
n 
3 
El
ut
io
n 
4 
L y
sa
te
 
El
ut
io
n 
5 
50- 
36- 
kDa 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. GST purification of p38α MAPK, p38α MAPK mutants and ATF2. In this figure a 
representative coomasie stained 12 % SDS polyacrylamide gel showing all the steps during the GST 
purification, is depicted. As can be seen, during the bacterial lysate clearspin a large amount of the 
desired protein is lost. However, there is still enough protein eluted for the p38 kinase assay to be 
performed. Elutions 1-4, containing the overexpressed protein, were pooled.
 
2.2.1.3 p38α Kinase Assay on GST-Purified p38α Mutants to Assess their 
Activity  
In order to assess the activity of the p38α MAPK mutants generated we performed a 
kinase assay with the GST-purified wild-type and mutant p38α MAPKs. As described 
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in the introduction, p38α is a kinase that can activate downstream targets, including 
other kinases like MAPK-activated protein kinase 2 and transcription factors, like 
ATF2, through phosphorylation. ATP is required for this reaction to take place. In this 
study, the activity of p38α was assessed by examining the degree of ATF2 
phosphorylation by quantifying the incorporation of [γ-32P] ATP in ATF2 using 
phosphoimaging, as previously described by Jiang, Y. et al, 1997 157. The reaction 
was performed by incubating the GST-purified wild-type and mutant p38α MAPKs 
with GST-ATF2 for 20 mins at 37 °C, in the presence of [γ-32P] ATP. The reactions 
were then ran on 12% SDS polyacrylamide gels, and subsequently exposed to a 
phosphoimager. Quantification was performed by using the program ‘RANDAMES’ 
that allowed us to quantify the volume of each band in the autoradiograph, but also 
the coomassie stained gel. By dividing the amount of phosphorylated ATF2 as 
measured from the autoradiograph, with the total amount of ATF2 as measured from 
the coomassie stained gel, we identified the p38α mutant D176A/Y323L as the most 
active one (Fig. 29) From this activity assay we also identified a p38α mutant that 
was less active than the wild-type p38α MAPK, mutant Y323L.  
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Figure 29. p38α MAPK kinase assay. The activity of the p38α MAPK mutants was assessed by 
quantifying the incorporation of [γ-32P] ATP into ATF2 in the presence of GST-purified wild-type p38α 
and mutants. From this assay the mutant D176A/Y323L was revealed as the most active. Mutant 
Y323L appeared to be less active than wild-type p38α. This is a representative experiment of three. 
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2.2.1.4 Dual-Luciferase ATF2 Reporter Assay to Assess Mutant Activity in 
Mammalian (HEK293) Cells   
After quantifying the activity of the p38α mutants overexpressed in E.coli cells, we 
went on to analyse their activity in mammalian cells. For this reason, we subcloned 
the wild-type and p38α mutants into the mammalian vector pIRESpuro, (see 
Appendix IV), which promotes the stable expression of the gene of interest over time 
in culture. In order to subclone wild-type p38α and the p38α mutant cDNA into the 
pIRESpuro vector we used a BamHI digestion. Clones with the correct orientation of 
the insert were selected by digesting with EcoRI (Fig. 30). 
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Figure 30. Subcloning of wild-type p38α and mutants into the pIRESpuro vector. EcoRI 
digestion was used to confirm the correct orientation of the wild-type and mutant p38α cDNA 
subcloned into the pIRESpuro vector. In the figure clones 2, 5, 8, 14 and 15 have the correct 
orientation. Correct orientation=5934 & 306 bp, Wrong orientation= 5440 & 800 bp. 
2 5 8 9 10 11 14 15 
1kb - 
500 bp - 
 
The activity of the mutant forms of p38α compared to wild-type, in mammalian cells, 
was assessed by performing ATF2 reporter assays 158. This reporter system is 
composed of the transcription factor GAL-ATF2 and the GAL4-driven firefly 
luciferase reporter gene (LUC), on different constructs. Higher p38α activity leads to 
increased luciferase expression. HEK293 (Human Embryonic Kidney Cells) cells 
were cotransfected with wild-type p38α or a mutant form, the two constructs of the 
firefly luciferase reporter system, and a control renilla luciferase reporter vector used 
to normalize experimental variations. From this dual-luciferase reporter assay, we 
confirmed the result we had seen previously, i.e. that the mutant form of p38α, 
D176A/Y323L has the highest activity, compared to wild-type p38α (Fig. 31). Activity 
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in all experiments for this mutant was between 3 & 5-fold higher than wild-type p38α 
MAPK.  
 
 
 
 
 
 
 
 
 
 
ATF2-GAL - + - + + + + + + + 
GAL-LUC + - + + + + + + + + 
Renilla + + + + + + + + + + 
wt p38α + + - - + - - - - - 
D176A - - - - - - - - - + 
Y323L - - - - - - - - + - 
F327L - - - - - - - + - - 
D176A/Y323L - - - - - + - - - - 
D176A/F327L - - - - - - + - -  
 
 
 
 
 
 
 
 
 
Figure 31. Dual-luciferase ATF2 reporter assay. A dual-luciferase reporter assay was carried out 
in HEK293 cells to evaluate the activity of the previously generated p38α mutants, in mammalian 
cells. Cells were cotransfected with either wild-type p38α or a mutant form, the two constructs of the 
firefly luciferase reporter system (ATF2-GAL and GAL-LUC), and a control renilla luciferase reporter 
vector used to normalize experimental variations. The mutant with the highest activity was found to 
be D176A/Y323L. 
 
2.2.1.5 Subcloning of the p38α Mutant D176A/Y323L into the ROSA26-CAGS 
Targeting Vector to Generate the p38αCA Targeting Construct 
Once we had confirmed that the mutant form of p38α, D176A/Y323L, was the one 
with the highest activity compared to wt p38α, the cDNA was subcloned into the 
ROSA26-CAGS targeting vector: This vector allows targeting of a desired transgene 
to the ROSA26 locus, from where it can be expressed ubiquitously in the whole body 
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of a mouse under the control of a CAGS promoter 159. Furthermore, since the 
transgene is placed after a transcriptional STOP cassette, which is flanked by two 
loxP sites, it can only be expressed in the presence of a Cre recombinase. 
Therefore, this construct allows for temporal control of transgene expression (Fig. 
32, top). Subcloning into this targeting vector was achieved by amplifying the mutant 
p38α cDNA with primers that had been designed to insert AscI sites at the 5’ and 3’ 
end. This fragment was then inserted into the AscI site of the targeting vector, which 
is positioned on the 3’ end of the loxP flanked STOP cassette (Fig. 32, top). 
Orientation of the inserted gene was examined through restriction digestion with 
EcoRI (Fig. 32, bottom) 
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Figure 32. Subcloning of the mutant p38α D176A/Y323L (p38αCA) into the ROSA26-CAGS 
targeting vector. The mutant p38α was inserted at the AscI site of the targeting vector, which is 
placed immediately after the loxP flanked transcriptional STOP cassette. The correct orientation of the 
insert was examined with EcoRI digestion. The fragment sizes for correct insertion were: 8373 bp, 
4303 bp, 2632 bp and 1845 bp. In the figure clones 3, 6 and 7 have the correct insert. LAH (Left Arm 
of Homology), RAH (Right Arm of Homology) NEO (Neomycin resistance gene), IRES (Internal 
ribosomal entry site), PA (PolyA), GFP (Green fluorescent protein), FRT (Flp recombination site), SA 
(Splice acceptor), DTA (Diptheria toxin). 
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2.2.1.6 Targeting of the Mutant p38α Transgene to the ROSA26 Locus 
After subcloning the p38α mutant D176A/Y323L into the ROSA26-CAGS targeting 
vector and confirming the correct orientation of the insert, we then went on to target 
the construct to the ROSA26 locus (Fig. 34). In order to do this, the final construct 
was linearized with AsisI digestion (Fig. 33). It was then introduced into Bruce 4 ES 
cells through electroporation. After positive (neomycin resistance) and negative 
(diphtheria toxin) selection, two 192 clones were picked, and nine homologous 
recombinants were identified by southern blotting with a 5’ probe (Fig. 35) external to 
the targeting vector.  
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 Figure 33. Linearization of the p38αCA targeting vector for electroporation into BRUCE 4 ES 
cells. Linearization of the final targeting vector containing the most active p38α mutant cDNA was 
achieved with AsisI digestion. Uncut vector was use as a control. 
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Figure 34. The p38αCA targeting strategy 
Insertion of p38αCA into the ROSA26 locus by homologous recombination in mouse BRUCE 4 ES cells.  
After Cre-mediated excision of the STOP cassette, p38αCA is expressed under the control of the CAGS 
promoter. Digestion with EcoRI allowed us to identify targeted clones with an external 5’ probe. EcoRV 
digestion and Southern Blotting with a NEO probe allowed us to exclude any random integration. In 
contrast with the wt ROSA26 locus that gave a band of ∼16kb, the recombinant ES clones showed a band 
of ∼7.2 kb with the 5’ probe, after EcoRI digestion.  
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Figure 35. Southern blotting of ES clones targeted with the p38αCA vector.Southern blotting of 
the 192 ES clones picked, revealed 9 clones positive for homologous recombination when digesting 
with EcoRI and probing with a the 5’ probe depicted in figure 34. They are indicated with red arrows. 
Wild-type bands ~16kb, targeted bands ~7.2kb. 
∼ 16 kb 
∼ 7.2 kb 
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The positive ES cell clones were further expanded and reconfirmed through 
Southern blotting for the 5’ probe (Fig. 36A). Blotting with a NEO probe excluded 
random integration, but also revealed some clones previously shown to be positive 
with the 5’ probe that were not positive for NEO, like 1.E11 (Fig. 36B).  
 
 
A 
 
 
 
 ∼ 16 kb 
 
∼ 7.2 kb 
 
 
 
 
 
 
 
B  
 
 
 ∼ 12 kb 
 
 
 
 
 
 
 
 
 
Figure 36. Confirmation of homologous recombination in ES clones targeted with the p38αCA 
vector. The ES cell clones that appeared positive for homologous recombination from the initial 
screening with Southern Blotting, were further grown in 10cm3 and DNA extracted from these clones 
was used to confirm that we had indeed picked and expanded the correct clones, by (A) Southern 
Blotting with the external 5’probe. All 9 clones were confirmed for homologous recombination. Wild-
type bands ~16kb, targeted bands ~7.2kb. (B) Random integration was excluded by digesting with 
EcoRV and probing with a NEO probe.  
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To test whether the constitutively active p38α would be expressed upon Cre-
mediated recombination in these ES clones we made use of HTNC again that can be 
used efficiently to mediate recombination of loxP flanked alleles in ES cells 154. If Cre 
recombination occurs in these cells, the STOP cassette will be excised, activating 
expression of the active p38α and also of GFP Treatment of ES cells with 5μM 
HTNC showed nearly 100% of ES cells expressing GFP, by FACS analysis (Fig. 
37A). Immunoblotting for p38α and GFP on cytosolic extracts prepared from HTNC 
treated ES cells confirmed GFP expression in ES clones positive for homologous 
recombination, but also overexpression of p38α, compared to wt cells (Fig. 37B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0μM 2μM 5μM
 
 Gated cells 
 
Figure 37. Treatment of ES clones positive for homologous recombination with HTNC. Positive 
clones were grown on 6-well plates at a density of 2x105 on feeder MEFS and treated with HTNC as 
described in the methods. (A) FACS analysis of these cells showed GFP expression in nearly 100% of 
cells at a concentration of 5μM of HTNC. In the figure, clone 1.D6 is depicted as an example of GFP 
expression. (B) Immunoblotting with GFP and p38α antibodies showed GFP expression and increased 
p38α expression in p38αCA cells treated with HTNC. Negative controls were wild-type ES cells and 
p38αCA cells not expressing GFP when examined with FACS analysis (e.g. clone 1.E11). 
 
 
A 
B 
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2.2.1.7 From ES Cells to Mice - Chimeras and Germline Transmission  
Once the ES clones positive for homologous recombination had been confirmed, two 
of them, 1.B4 and 2.A3, were injected into C57BL/6 blastocysts. These injections did 
not give rise to any chimeras, maybe due to the quality of the ES cells. From a 
second injection, in CB20 blastocysts, we obtained four male chimeric mice, two 
from clone 2.A3 (# 850 and # 851) and two from clone 1.B4 (# 861 and #862), with a 
chimerism of 70-80% recognized through color coating (Table 2). These male 
chimeras were then bred with wild-type C57BL/6 female mice in order to achieve 
germline transmission of the p38αCA transgene. Mice with germline transmission 
were identified by color coating, PCR and Southern Blotting. The result from 
Southern Blotting was puzzling since mice with germline transmission gave a ∼2kb 
band higher than was expected. However, we still proceeded with breeding these 
mice, since this problem has been seen before with other ROSA26 targetings but the 
mice were still functional (Table 2 and Fig. 38). From these breedings germline 
transmission (GLT) was only obtained from clone 2.A3, chimera # 850. 
 
 
 
 
 
 
 
 
Clone ES-cell 
line 
Blastocyst 
strain 
Chimera Bred with Comments 
2.A3 Bruce 4 CB20 
# 850 male 80% 
# 851 male 70% 
C57BL/6 female 
GLT 
- 
1.B4 Bruce 4 CB20 
# 861 male 80% 
# 862 male 70% 
C57BL/6 female 
- 
- 
 
 
 
Table 2. Chimeric mice and germline transmission obtained from the injection of BRUCE 4 ES 
cells carrying the p38αCA transgene in the ROSA26 locus. 
 
 
 
 
Two positive ES clones, 2.A3 and 1.B4, were injected into CB20 blastocysts in order to obtain chimeric 
mice for the p38αCA transgene. From this injection we obtained two male chimeras from each clone 
with a chimerism of 70-80%. Breeding of these chimeras with female C57BL/6 mice gave germline 
transmission from clone 2.A3 only. Germline transmission was identified through color coating 
(black/brown), PCR and Southern Blotting. 
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Figure 38. PCR and Southern Blotting for the identification of germline transmission of p38αCA.  
(A) PCR was performed to examine if germline transmission had occurred from the breeding of male 
chimeric mice with female C57BL/6 mice. Germline transmission was obtained from chimera # 850 (ES 
clone 2.A3), according to our PCR results. The primers used are depicted in the figure. Wild-type (wt) 
band = 570 bp, Floxed (fl) band = 380 bp. (B) We also performed Southern Blotting with the 5’ probe 
described previously, after digesting with EcoRI. The result from this was puzzling since mice with 
germline transmission, according to PCR results, had a band ∼2kb higher than expected (∼9kb). 
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2.2.1.8 GFP Expression in R26wt/p38αCALPC-KO Mice  
As an initial step, in order to confirm that the construct was functional, we crossed 
mice heterozygous for the p38αCA transgene with AlfpCre mice, which express Cre 
specifically in liver parenchymal cells (hepatocytes). The aim of this experiment was 
to isolate primary hepatocytes from these cells to examine GFP expression by 
performing FACS analysis. p38αCA heterozygous mice positive for AlfpCre 
(R26wt/p38αCALPC-KO) that were obtained from this breeding were used to isolate 
primary hepatocytes and look at GFP expression. p38αCA heterozygous littermates, 
negative for AlfpCre expression were used as negative controls. This experiment 
indicated that the construct inserted into these mice was functional, since we 
observed GFP expression in the presence of Cre recombinase in hepatocytes (Fig. 
39).  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 Figure 39. GFP expression in R26wt/p38αCA
LPC-KO mice. FACS analysis of primary hepatocytes 
isolated from R26wt/p38αCACLPC-KO mice showed GFP expression in these mice, which was not 
present in WT (wild-type) mice. Panels left: Top - gated primary hepatocytes, middle and bottom - 
GFP expression. Panel right: Comparison of GFP expression in Cre positive and negative cells.  
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We are now continuing the characterization of these mice by performing 
immunoblotting in order to determine if p38α is overexpressed, but also by 
performing activity assays as described previously in order to determine whether the 
overexpressed protein is hyperactivated compared to wild-type. Finally, we are 
breeding these mice to Deleter Cre mice that express Cre throughout the whole 
body, in order to determine the systemic effect this hyperactive form of p38α may 
have on mice. 
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2.2.2 Generation of p38αKD (Kinase Dead) Mice 
Given the fact that p38 MAPK exists in four different isoforms and therefore when 
knocked out completely its activity may be compensated by other isoforms, but also 
that it may display another function that is not dependant on its kinase activity, we 
decided to generate mice that would express a kinase-dead form of this protein. 
 
2.2.2.1 The p38αKD Targeting Construct 
In order to generate mice expressing a kinase-dead form of p38α MAPK, we took 
advantage of a previously published mutation that is conserved between kinases 
and eliminates the kinase activity of the protein. More specifically, the amino acid 
residue lysine 53 that is located in exon 2 of the p38α MAPK locus and is essential 
for kinase activity was mutated to an arginine residue (K53R) to generate a kinase 
inactive form of p38α MAPK (Kumar, S. et al., J. Biol. Chem., 1995). 
After introducing this mutation into exon 2 of the p38α genomic sequence, we then 
went on to generate the targeting construct that would allow the generation of mice 
harbouring this mutation. In the generation of our construct we took advantage of the 
mutated asymmetric loxP sites, lox66 and lox71160. Normally, when positioning two 
loxP sites in the head-to-head or opposite orientation, the intervening sequence is 
inverted in the presence of Cre recombinase. However, this inversion is not 
continuous and is reversed upon the removal of Cre recombinase. In the case of the 
mutant lox66 and lox71 sites, after the first Cre-mediated recombination on wild-type 
and one double mutant loxP site a re formed (see fig. 40B). The latter however 
displays a very low affinity for Cre recombinase. Consequently, Cre-mediated 
recombination in the mutated Cre/loxP system has a favorable forward reaction 
equilibrium as depicted in the figure (Fig. 40B). 
In our p38αKD targeting construct, we made use of these mutated loxP sites to 
switch between the native and the mutated p38α MAPK exon 2. More specifically, 
we subcloned both the native and the mutated exon2 in opposite and inverse 
orientations between lo66 and lox71 (Fig.40A). This way, the native exon 2 would be 
expressed in the absence of Cre recombinase, whereas introduction of Cre into the 
system would lead to constant expression of the mutated exon2 by inversion. The 
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pEASY-FLIRT vector (Appendix I) was used to generate the final targeting construct 
harboring the mutated exon2. 
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Figure 40. The p38αKD targeting strategy. (A) The targeting construct. The kinase essential lysine 
residue 53, in Exon 2, was mutated to an arginine. Both, the normal and the mutant Exon2 were 
placed between the mutant lox66-lox71 sites in an inverted order as depicted in the figure. LAH=Left 
Arm of Homology, NEO=Neomycin Resistance Cassette, TK=Thymidine Kinase, K53R=Lysine to 
Arginine mutation (B) Cre-mediated recombination between lox66 and lox71 sites generates one wild-
type and one double mutant loxP site. Since the double mutant loxP site exhibits much reduced 
binding affinity for Cre recombinase, Cre- mediated inversion using the mutated Cre/loxP system 
prefers the forward reaction as indicated. Nucleotide sequences of loxP and its mutated derivatives 
are listed; mutated sequences are underlined. Arrows indicate non-palindromic core sequence. Image 
taken from: Nucleic Acids Research, 2002, Vol. 30, No. 17 e90© 2002, Oxford University Press. 
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2.2.2.2 Targeting of the p38αKD Construct to the p38α Locus 
Once the final construct was generated, we targeted the kinase-dead form of p38α to 
the p38α MAPK locus (Fig. 42). In order to do this, the final construct was linearized 
with NotI digestion (Fig. 41). It was then introduced into Bruce 4 ES cells through 
electroporation.  Three hundred eight-four clones were picked, and after positive 
(Neomycin) and negative (Thymidine kinase) selection, four homologous 
recombinants were identified by Southern blotting using a 5’ and 3’ probe external to 
the targeting vector (Fig. 43 and 44, respectively). Additional integrations were 
excluded in these positive clones by use of a neomycin probe. After confirmation of 
the clones by Southern Blotting again with the 5’, 3’ and NEO probe, using DNA 
prepared after further expanding these clones further on 10 cm3 (Fig. 45), all four 
clones were injected into C57BL/6 derived blastocysts.  
 
 
N
ot
I d
ig
es
tio
n  
U
nc
ut
 v
ec
to
r 
1k
b 
la
dd
er
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41. Linearization of the p38αKD targeting vector for electroporation into BRUCE 4 ES 
cells. Linearization of the final p38α kinase-dead targeting vector achieved with NotI digestion. Uncut 
vector was use as a control. 
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Figure 42. p38αKD targeting to the p38α locus. (A) Schematic of the wt p38α locus before homologous 
recombination. (B) The p38α locus after homologous recombination at Exon 2. Depicted are also the probes used to 
screen for homologous (5’ and 3’, BamHI digestion) and random recombination (NEO, ScaI digestion). (C) The Neo 
cassette was removed by Flp recombination, by crossing with Flp deleter mice. (D) In the presence of Cre, the 
region between lox66 and lox71 is inverted, leading to expression of the mutated Exon2. In this process one wt and 
one double mutant loxP site are generated. Since the double mutant loxP site exhibits much reduced binding affinity 
for Cre recombinase, Cre- mediated inversion using the mutated Cre/loxP system prefers the forward reaction as 
indicated. 
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Figure 43. P38αKD targeting - Screening for homologous recombinants with a 5’ probe. Southern Blotting 
with a 5’ probe performed on DNA prepared from the 384 clones picked, after a BamHI digestion, allowed us to 
identify 4 ES clones positive for homologous recombination. WT = 15kb, Floxed = 6.6kb. 
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 Figure 44. P38αKD targeting - Screening for homologous recombinants with a 3’ probe. Southern Blotting 
with a 3’ probe, performed on the same Southern Blots used for the 5’probe after stripping, showed that 
integration had also taken place on the 3’ end of the 4 ES clones identified for homologous recombination 
previously, with the 5 ‘ probe. WT = 15kb, Floxed = 8kb. 
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Figure 45. P38αKD targeting – Clone confirmation. ES clones positive for homologous recombination 
during screening with Southern Blotting were further expanded and clones were reconfirmed by Southern 
Blotting with the 5’ and 3’ probes used previously for screening. A NEO probe was also used (ScaI 
digestion) to exclude random integration. All 4 clones were confirmed. 
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2.2.2.3 From ES Cells to Mice - Chimeras and Germline Transmission 
Once the ES clones positive for homologous recombination had been confirmed, all 
four of them were injected into C57BL/6 derived blastocysts. From these injections 
we obtained four male and two female chimeras, five from clone 1.C5, one from 
clone 3.E10 and one from clone 4.A2. Clone 2.E10 did not give any offspring (Table 
3). Chimeras were identified through genotyping PCR (Fig. 46). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clone ES-cell 
line 
Blastocyst 
strain 
Chimera Bred with Comments 
1.C5 Bruce 4 C57BL/6 
# 4845 male 
# 4846 male 
# 4968 male 
# 4847 female 
# 4850 female 
C57BL/6  female  
 
 
C57BL/6 male 
-  
GLT 
- 
- 
- 
2.E10 Bruce 4 C57BL/6 - - - 
3.E10 Bruce 4 C57BL/6 # 4592 male C57BL/6 female - 
4.A2 Bruce 4 C57BL/6 # 4852 male C57BL/6 female 
- 
 
Table 3. Chimeric mice and germline transmission obtained from the injection of BRUCE 4 ES 
cells carrying the p38αCA transgene in the ROSA26 locus. 
Four positive ES clones, 1.C5, 2.E10, 3.E10 and 4.A2, were injected into C57BL/6 blastocysts in order 
to obtain chimeric mice. From this injection we obtained five male and two female chimeras in total. 
Breeding of these chimeras with female and male C57BL/6 mice respectively, gave rise to germline 
transmission from clone 1.C5 only. Germline transmission was identified through PCR and Southern 
Blotting. 
 
All the chimeras obtained were bred to C57BL/6 to produce mice with germline 
transmission. From all the chimeric breedings, only one gave mice where germline 
transmission was detected through genotyping and Southern Blotting. This was male 
4846 from clone 1.C5.  
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Figure 46. Identification of germline transmission through PCR and Southern blotting. (A) Genotyping 
strategy for p38αKD targeting. The primers used for amplification in the wt (top) and targeted (bottom) locus 
for chimera and germline identification are depicted in the figure. Germline transmission obtained from 
breeding the male chimera 4846 with a C57BL/6 female was identified through (B) PCR for the floxed and 
NEO bands and (C) Southern Blotting with a 5’ probe described previously. 
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2.2.2.4 In vivo NEO Deletion and Breedings 
Mice with germline transmission were crossed with Flp deleter mice to remove the 
NEO cassette so that it would not interfere with the proper expression of proteins. 
NEO deletion was determined by PCR using primers 4 & 5 that give a band of ∼ 
500bp only in the presence of the NEO cassette (see genotyping strategy fig. 46). 
Once we had obtained mice where the NEO cassette had been deleted, giving us 
heterozygous p38αKDFL/wt mice, these were bred with wild-type C57BL/6 mice in 
order to expand the line. We are also now breeding heterozygous mice in order to 
generate homozygous p38αKDFL/FL mutant mice. The homozygous mice can then be 
bred to Deleter Cre or other Cre lines for further characterization.  
 
2.2.2.5 Testing of Inversion in the Presence of Cre Recombinase 
Whilst the mice are breeding, once we had generated NEO deleted heterozygous 
mice, we isolated some BMDMs to test if the inversion in the presence of Cre 
recombinase was functional. This was achieved by treating the BMDMs with HTNC 
for 16hrs as described in the methods and isolating DNA to check for inversion by 
PCR and Southern Blotting. Inversion of the genomic sequence between the two 
mutant loxP sites was observed at all concentrations of HTNC used (1 & 2 μg/ml) in 
cells isolated from p38αKDFL/wt, but not from wild-type mice, giving us a first 
indication that the construct we designed is functional (Fig. 47). This result still has to 
be confirmed by Southern Blotting. Also, the catalytic activity of p38α MAPK in these 
mice still remains to be examined, in the presence of Cre recombinase. 
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Figure 47. Genotyping for inversion in p38αKD mice after Cre recombination. PCR on DNA 
isolated from HTNC treated BMDMs of p38αKDFL/WT mice, showed that inversion of the lox66-lox71 
flanked nucleotide sequence is functional. Wild-type band (as seen in fig 46)=430 bp, Floxed band 
(diagram top)=512 bp, Inverted band (diagram bottom)=552 bp. 
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3. Discussion 
3.1 The Macrophage and Endothelial-Cell Specific Role of 
p38α MAPK in Atherosclerosis 
p38α MAPK has previously been implicated in the development of atherosclerosis 
through various in vitro studies with the use of small molecule p38 inhibitors 
125,126,134,161,162 but also in vivo in a recent study by Seimon, T.A et al. 2009, where 
they describe an anti-apoptotic role for p38α MAPK in macrophages induced by ER-
stress. In this study we have investigated the macrophage and endothelial-cell 
specific role of p38α MAPK in atherosclerosis by taking advantage of the Cre-loxP 
recombination system to generate myeloid and endothelial-cell specific knockout 
mice, since the complete knockout of p38α MAPK has previously been described by 
several groups to be embryonically lethal because of severe defects in placental 
development 67, 70,133. The results that we present here, surprisingly and contrary to 
previous studies, show that p38α MAPK does not play a significant role in 
atherosclerosis development.  
 
3.1.1 p38α MAPK in Macrophages 
3.1.1.1 p38α MAPK Depletion Does not Affect Foam Cell Formation in vitro 
Lipid-laden macrophage foam cells are an early (‘fatty streak’) and persistent 
component of atherosclerotic lesions, formed by the accumulation of cholesteryl 
esters and triglyceride in cytoplasmic droplets 163. Binding and endocytosis of lipids 
like oxLDL by macrophages is a result of the expression of various scavenger 
receptors, like CD36, on their surface.  CD36, through functional and structural 
studies, has been characterized to be a member of the class B family of scavenger 
receptors with a substantial capacity to bind oxLDL as well as other ligands. Its 
importance in the initiation and perpetuation of atherosclerotic lesions has been 
shown in the past decade in various studies by its effect in reducing lesion formation 
when inactivated in ApoE deficient mouse models, the latest of which has also 
underlined its significance in comparison to another important scavenger receptor 
linked to atherosclerosis, SRA I/II 164, 165. In this study authors claim that absence of 
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SRA I/II in ApoE deficient mice does not confer any further protection against 
atherosclerosis than what is already achieved through CD36 165.  
With the use of pharmacological inhibitors, it has been demonstrated that p38α 
MAPK, but not ERK or JNK, is necessary and sufficient for the transactivation of 
PPAR-gamma, a nuclear receptor that has been shown to play a pivotal role in 
oxLDL-induced CD36 expression 125, 166. In accordance to this, it was also shown 
that the p38 specific inhibitor SB203580 blocked oxLDL exposed J774 cells from 
becoming foam cells 125. In our studies however, when exposing p38α MAPK 
macrophages to oxLDL and examining lipid uptake by FACS analysis, we did not 
observe any significant differences, compared to wild-type mice. This was also true 
for the mRNA expression levels of CD36, which were increased in both wild-type and 
knockout cells in the presence of oxLDL in a similar manner (data not shown).  
3.1.1.2 Only MIP-2α and IL-1β mRNA Expression Mildly Affected in p38α 
Depleted Macrophages, in vitro 
Macrophages have also been described to play a key role in disease progression as 
inflammatory mediators 163. Once monocytes have entered the arterial intima, and 
differentiated into macrophages under the influence of the macrophage-colony 
stimulating factor (MCS-F), besides scavenger receptors, they also express other 
pattern recognition receptors, like Toll-like receptors (TLRs). These TLRs can be 
activated by factors such as LPS, heat shock protein 60 (HSP60), oxLDL and other 
ligands that instigate the production of many proinflammatory cytokines, MMPs and 
other inflammatory mediators like nitric oxide (NO) and endothelin-1, by 
macrophages 80. This response to TLR ligation is mediated by the activation of 
nuclear factor- B (NF-κB) and MAPK signaling pathways 167, 168, 169, including p38α 
MAPK. Genetic deficiency of TLR4, the TLR linked to inflammatory responses to 
oxLDL when in complex with CD14, but also its signal transducing adaptor molecule 
myeloid differentiation primary-response gene 88 (Myd88), has been shown to 
reduce plaques in mice 170, 171. 
Since, p38α MAPK is implicated in the expression of proinflammatory cytokines, 
chemokines, MMPs and other inflammatory mediators in atherosclerosis, 
downstream of TLRs, we decided to examine the expression of a panel of these 
mediators in macrophages after oxLDL stimulation. In this analysis, the only 
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difference we observed was a downregulation in MIP-2α and IL-1β, a response that 
has been previously shown in LPS stimulated macrophages also isolated from 
LysMCre mice 28. IL-1β and MIP-2α, which are both strongly induced in monocytes in 
atherosclerosis, are important mediators in the progression of this disease. ApoE 
deficient mice lacking IL-1β showed a 30% decrease in the severity of 
atherosclerosis that was attributed to the downregulation of MCP-1 and VCAM-1 
expression both at the mRNA and protein level 172. MIP-2α (IL-8 in humans), a CXC 
chemokine, was initially thought to be insignificant as far as atherosclerosis 
development is concerned, since it is mainly responsible for neutrophil recruitment, 
which are particularly scarce in atherosclerosis. However, recent reports suggest 
that it may trigger firm adhesion of monocytes to vascular endothelial cells, 
particularly under flow conditions, by binding to the CXC chemokine receptor CXCR2 
173. Furthermore, bone marrow transplantation studies demonstrated that the 
absence of the CXCR2 equivalent IL-8 receptor homologue resulted in diminished 
monocyte recruitment and reduced lesion size in the LDL receptor (-/-) model of 
atherosclerosis 174. However, in a recent study concerning IL-8, it was also shown 
that reduction in this chemokine under atheroprone flow conditions, leads to an 
increase in VCAM-1 expression, suggesting a limiting role for the inflammatory 
response in endothelial cells via VCAM-1 modulation 175. From these results, and 
given the findings of these previous studies, we hypothesized that p38α MAPK may 
not act as a mediator in foam cell formation in macrophages with respect to 
atherosclerosis, but it may contribute to this disease by playing a role in the 
recruitment of macrophages to the arterial intima, both by chemokine attraction 
(MCP-1 and MIP-2α) but also by promoting adhesion to the endothelial cell layer 
through VCAM-1 upregulation. On the other hand, taking this contradictory role of IL-
8 into consideration, increased VCAM-1 expression caused by reduction of MIP-2α 
(IL-8), could counterbalance the effect caused by the downregulation of IL-1β.  
3.1.1.3 Depletion of p38α MAPK in Macrophages Does not Affect 
Atherosclerosis Development in vivo 
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The results we obtained from our in vitro experiments, as described above, pointed 
towards a pro-atherogenic role for p38α MAPK in macrophages, and so depletion of 
this kinase should lead to a reduction in atherosclerosis development to some 
extent, due to a reduction in monocyte recruitment to the arterial intima. However, 
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when feeding groups of male and female macrophage-specific p38αMY-KO/ApoE-/- 
and their ApoE-/- littermates a cholesterol rich ‘western diet’ for 10 weeks, we did not 
observe any significant differences in atherosclerotic plaque development either in 
the aortic sinus or the whole aorta of these mice. This observation correlates with 
that recently published by the group of Ira A. Tabas, Columbia University, New York 
149. Consistent also with our results, atherosclerotic lesion size was also unaffected 
when a p38 inhibitor was given to ApoE-/- mice infused with angiotensin II 176. So, 
while other studies have shown that macrophage deletion of p38 MAPK has a 
marked effect on the reduction of inflammation in murine models of skin injury and 
septic shock 177, in our ApoE-/- model of atherosclerosis we found no reduction in 
lesion size.  
Further confirmation to the fact that p38α MAPK is not an important mediator in 
atherosclerosis development in the context of macrophages was provided by real-
time PCR (qRT-PCR) analysis on the expression of a panel of cytokines chemokines 
and adhesion molecules on RNA isolated from the aortic arch of p38αMY-KO/ApoE-/- 
and ApoE-/- littermates after 10 weeks on a cholesterol rich ‘western diet’. Although 
p38α MAPK has been shown to regulate the expression of many genes involved in 
the initiation and progression of atherosclerotic lesions 7,61,70,150,151, an effect thought 
to be mediated via a mechanism involving messenger RNA turnover and protein 
translation 3,61, we only observed a slight upregulation in most of the genes tested 
but no statistically significant differences. Not even in MIP-2α and IL-1β, which were 
both downregulated in vitro when stimulating macrophages with oxLDL. These 
results further confirmed that macrophage-specific deletion of p38α MAPK does not 
affect lesion size, and again challenged our hypothesis that it could affect 
atherosclerotic lesion development by promoting recruitment of macrophages to the 
arterial intima. 
3.1.1.4 Markers of Advanced Atherosclerotic Plaque Progression not Altered in 
Macrophage-Specific p38α MAPK Knockout Mice 
Although the above evidence was sufficient to claim that the macrophage-specific 
role of p38α MAPK in atheroma formation is insignificant, the recent study by 
Seimon, T.A et al. 2009 perturbed us to continue with the characterization of the 
plaques because of their controversial findings in plaque progression. In their study, 
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they claim that although there are no observable differences in plaque size between 
p38αMY-KO/ApoE-/- and ApoE-/- mice, when deleting p38α MAPK, plaques seem to be 
more advanced. A significant reduction in collagen content was observed, together 
with a dramatic increase in mean necrotic area formation. They conclude that 
dramatic increase in necrotic core formation is due to a role of p38α MAPK in 
suppressing ER-stress induced macrophage apoptosis, subsequently promoting 
plaque necrosis and advanced atherosclerotic lesions. However, these findings are 
controversial since many studies have shown that apoptosis of macrophages can be 
beneficial in atherosclerosis by reducing plaque size 178, 179. For example, 
administration of TRAIL to diabetic ApoE knockout mice induces apoptosis in 
established plaques, with most dying cells being macrophages and leads to reduced 
plaque size and less inflammation 178. Also, macrophage death on its own is not 
adequate to increase necrotic core formation, requiring other processes including 
accumulation of both intracellular and extracellular lipid and death of a number of cell 
types, like vascular smooth muscle cell (VSMC) apoptosis. VSMC apoptosis has 
been shown to effectively increase necrotic core sizes (by more than 200% in some 
studies), in the absence of macrophage apoptosis 180, 181. Indeed, when quantifying 
necrotic core formation, collagen content and foam cell content in our mice, we did 
not observe the effects described by Seimon, T.A et al. 2009. 
 
3.1.1.5 Can JNK2 Overexpression and Activation Counterbalance the Effect of 
p38α MAPK Ablation? 
In conclusion, our results suggest that p38α MAPK in macrophages does not play a 
significant role in atherosclerosis development. As this result is puzzling, since it 
does not correspond to the studies carried out in vitro thus far with p38-specific 
inhibitors, we can hypothesize that this is the case either because a systemic effect 
of p38 inhibition is required to cause a significant effect in atherosclerosis 
development, or p38 has a more pronounced role with respect to atherosclerosis in 
another cell type involved in this disease, like vascular smooth muscle cells, e.g., 
where it has been described to be involved in their migration and proliferation 127. 
Finally, it could be that the effects observed by these inhibitors are not so specific for 
p38α MAPK but can also act on other kinases, like JNK2, as has been previously 
described 47,182, where higher concentrations of the inhibitor also inhibited JNK2 
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phosphorylation, but not JNK130. This could be particularly important in the 
development of atherosclerosis, since JNK2 but not JNK1 has also been shown to 
have a significant role in atherosclerosis development by promoting foam cell 
formation 155. Since ablation of p38α MAPK leads to hyperactivation of JNK2 28,75, 
maybe this could lead to increased atherosclerosis development and counteract the 
reduction that is expected by diminishing p38α MAPK expression. This effect is 
probably missed in experiments with small molecule inhibitors if they also cause a 
reduction in the activation of other kinases like JNK2.  
 
3.1.2 p38α MAPK in Endothelial Cells 
3.1.2.1 p38α MAPK Depletion in Endothelial Cells Leads to Reduction of 
Expression in Atherosclerosis Markers like VCAM-1, in vitro 
Endothelial cells form the ‘first line’ of combat in the development of atherosclerosis. 
When activated by various factors like oxLDL and cytokines (e.g. TNF and IL-1beta), 
they can express adhesion molecules and chemokines that recruit monocytes and T-
cells to the arterial intima. One of the roles that has been attributed to p38α MAPK in 
endothelial cell activation is the regulation of adhesion molecule expression like 
VCAM-1 61, 183 and expression of various proinflammatory cytokines and chemokines 
3,7,63, 184. Also, stimulation of endothelial cells with oxLDL has been shown to lead to 
activation of p38 via phosphorylation 185. For this reason we stimulated primary lung 
endothelial cells in vitro with oxLDL and tested with real-time PCR (qRT-PCR) the 
expression of a panel of cytokines, chemokines and adhesion molecules known to 
be involved in atherosclerosis development but also regulated by p38α MAPK, on 
RNA isolated from these cells. mRNA levels of VCAM-1, an endothelial adhesion 
molecule known to be regulated synergistically by p38α MAPK and NF-kappaB 186 
and is important for atherosclerosis development 187, 188 was strongly reduced in 
oxLDL stimulated p38α MAPK knockout primary lung endothelial cells compared to 
wild-type cells. Gro-KC, deficiency of which has been associated with a loss of 
intimal macrophages and attenuated disease progression throughout time within 
established fatty streak lesions 173 was also strongly reduced. IP-10, an IFN-gamma 
inducible chemokine, was also significantly reduced. This chemokine has been 
shown to be highly and differentially expressed by human atheroma-associated cells 
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within lesions 189 and to attenuate atherosclerosis development in ApoE deficient 
mice by diminishing the influx of effector T-cells, thereby correcting the local balance 
with regulatory T-cells 190. Finally, MCP-1 that is a molecule critical for the initiation 
and development of atherosclerosis since it recruits monocytes and macrophages to 
the vessel wall via its receptor CCR2 was also significantly downregulated upon 
oxLDL stimulation. Studies with both MCP-1 and CCR2 deficient mice 191, 192 have 
both shown a marked decrease in lesion formation, highlighting the importance of 
this molecule in this disease. Again, like in our in vitro experiments with p38α MAPK 
knockout macrophages, these results pointed towards a pro-atherogenic role for this 
molecule in the endothelium. More specifically, it seemed to be involved in the 
recruitment of monocytes and macrophages into the arterial intima. 
 
3.1.2.2 Downregulation of JNK Activation Caused by p38α MAPK Ablation 
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The MAPK JNK, also a stress-activated kinase like p38 MAPK has also been 
implicated in atherosclerosis development, with respect to endothelial cell function. 
Several laboratories have previously reported a possible role for JNK in endothelial 
cell activation 193, 194, 195. It has been implicated in the expression of adhesion 
molecules by the endothelium, like E-selectin, ICAM-1 and VCAM-1, just like p38α 
MAPK 196, 197, 198, 199. Since it has previously been shown that ablation of p38α MAPK 
in many cell types, including macrophages and liver cells28, 75, can lead to increased 
activation of JNK therefore suggesting a role for p38α MAPK in the regulation of this 
molecule, we decided to examine JNK activation in p38α MAPK deficient endothelial 
cells. This was a concern for us since JNK has also been implicated in 
atherosclerosis development 155, and its hyperactivation in the absence of MAPK as 
we previously hypothesized for macrophages, could counterbalance the effect of 
p38α MAPK ablation. According to the results obtained from JNK knockout mice, 
ablation of this protein did not appear to severely affect endothelial cells 200, but 
nevertheless we stimulated primary lung endothelial cells with oxLDL and examined 
the phosphorylation of JNK. Surprisingly, immunoblotting for p-JNK showed 
decreased activation in cells where p38α MAPK had been deleted with HTNC 
treatment. This downregulation of JNK provided further evidence that p38α MAPK 
may have a pro-atherogenic role in endothelial cells, and in addition to promoting 
atherosclerosis itself, could also work to regulate other kinases involved in 
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atherosclerosis development. This result also excluded the possibility that 
hyperactivation of JNK could counterbalance the effects exerted by ablation of p38α 
MAPK in endothelial cells. 
 
3.1.2.3 In vivo Endothelial-Cell Depletion of p38α MAPK Did not Have a 
Significant Effect on Atherosclerosis Development 
Our in vitro results, with primary lung endothelial cells as described above pointed us 
towards a pro-atherogenic role for p38α MAPK, since its ablation resulted in the 
downregulation of expression of markers of atherosclerosis, such as VCAM-1. This 
hypothesis was also backed up by various in vitro and in vivo studies concerning 
atherosclerosis development that also delegate a pro-atherogenic role to this 
molecule in the endothelium, by mediating endothelial dysfunction, an important step 
in atherosclerosis initiation since it leads to adhesion molecule, proinflammatory 
cytokine and chemokine expression 201, 61, 63, 133, 134, 135, 136, 28. For example, selective 
inhibition of p38 MAPK dose-dependently reduces TNF or LPS-induced ICAM-1 
expression in cultured HUVECs 201. Patients with coronary artery disease have a 
significantly higher basal p38 MAPK phosphorylation and a reduced number of 
endothelial progenitor cells (EPCs), which are vital for angiogenesis/vascular repair. 
Inhibition of p38 MAPK with SB203580 (a selective inhibitor for p38α and p38β) or 
transfection with a dominant-negative p38 MAPK-expressing adenovirus significantly 
increases the basal number of endothelial progenitor cells in these patients 202. In 
addition, C-reactive protein inhibits endothelium-dependant NO-mediated dilation in 
coronary arterioles by activating p38 MAPK and reduced nicotinamide adenine 
dinucleotide phosphate oxidase 203. Moreover, lysophosphatidylcholine (LysoPC) 
which is a component of oxLDL induces apoptotic signals in endothelial cells through 
the p38 signaling pathway, as shown with SB203580 inhibitor studies 204. Finally, 
activation of p38 MAPK in the endothelium through disturbed blood flow, an 
important component in atherosclerosis determining where lesions occur in the 
aorta, can lead to VCAM-1 expression through an AKS1–dependant pathway, 
promoting leukocyte adhesion, inflammation and atherosclerosis 205. 
Despite all these studies attributing a pro-atherogenic role to this molecule, when 
analyzing male and female littermates for atherosclerosis development after 10 
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weeks of cholesterol rich ‘western diet’, we did not observe any significant 
differences either in plaque size at the aortic sinuses or lesion size in the whole 
aorta. Furthermore, characterization of the stage of the plaques in the two different 
genotypes did not reveal any differences either in foam cell formation, collagen 
content or necrotic core formation, which are all characteristics of advanced plaques. 
A final confirmation to the fact that there was no apparent effect of the endothelial-
specific deletion of p38α MAPK in atherosclerosis development compared to their 
ApoE-/- littermates was the absence of differences in cytokine chemokine and 
adhesion molecule expression. 
3.1.2.4 Opposing Role of p38α MAPK in the Endothelium in Atherosclerosis 
Development Could Account for the Lack of Phenotype in p38αEC-KO/ApoE-/- 
Mice 
In conclusion, as for the macrophage-specific knockout of p38α MAPK, endothelial-
specific ablation of this protein does not affect atherosclerosis development either. 
This result could possibly be explained by the fact that there have also been several 
studies published, that attribute an opposing, i.e. atheroprotective role, to p38 MAPK 
in the endothelium, and that these opposing effects counterbalance its pro-
atherogenic effect. For example, sheer stress can also lead to the upregulation of the 
Unfolded Protein Response (UPR) regulator, GRP78, by an α2β1-dependant 
mechanism in endothelial cells 206, 207. Also, in response to flavonoids like black tea 
polyphenols, p38 MAPK activates eNOS in endothelial cells by an estrogen receptor 
a-dependant pathway, leading to increased NO production and thereby improved 
endothelial function 208. From these studies, and our results, we can see that p38α 
MAPK signaling in the endothelium, with respect to atherosclerosis, is much more 
complex than expected. So, it could be that when deleting p38α we don’t only 
remove its pro-atherogenic, but also its atheroprotective effects, and this is why we 
do not see any differences in the phenotype of endothelial-specific knockout mice 
compared to wild-type mice after 10 weeks of a cholesterol rich ‘western diet’. 
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3.2 The Generation of p38αCA and p38αKD Mice  
The two new p38α MAPK mouse models, p38αCA and p38αKD described in this 
study, were initially generated to complement our studies with the ApoE-/- mouse 
model in atherosclerosis. However, both of these mouse models can be utilized for 
other exciting studies that will allow us to shed light and elucidate further the function 
and signaling pathways this molecule is involved in, in a variety of diseases and in 
specific cell types since both the constitutively active but also the kinase dead form 
of p38α MAPK are only activated in the presence of the Cre recombinase.  
 
3.2.1 p38αCA Mice and their Applications 
In this study, by taking advantage of two point mutations (D176A and Y323L), 
previously described in the p38 yeast homologue Hog1 to render this protein 
catalytically and biologically active 146, 156, we generated a mutant form of p38α 
MAPK that appears to be 3∼5-fold more active than the native p38α MAPK in the 
complete absence of any upstream activators or external stimuli. The advantage of 
generating a mouse model where a specific MAPK is hyperactivated is the fact that 
we can follow the biochemical and physiological consequences of the specific MAPK 
more closely. This is because we do not require an extracellular stimulus or to 
express an active form of a component that functions upstream of that MAPK, 
therefore activating more than one MAPK and evoking many cellular responses. We 
have now generated mice carrying this hyperactive form of p38α MAPK in the 
ROSA26 locus, and have already established GFP expression in hepatocytes of 
mice crossed to the AlfpCre line that is only expressed once Cre recombination has 
occurred as previously described. Once we have also established the higher 
activation of this protein compared to wild-type p38α MAPK by performing kinase 
assays, these mice will be a very useful tool in many applications. Some of examples 
of possible applications are described below. 
An interesting study where this new mouse model can be utilized is in the elucidation 
of the mechanisms via which p38α MAPK mediates cell survival, which has not been 
studied thus far, as opposed to its well known role in cell death 209 Also, since p38 
MAPK is mostly considered to be associated with cell death, it is also important to 
answer the question as to how it discriminates its targets to mediate cell-death from 
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those to mediate cell survival. Finally, the p38αCA model is also an invaluable 
genetic tool that will allow us to obtain mechanistic insights in the tumor suppression 
function of p38α MAPK. Various mechanistic insights have started to emerge for the 
past few years concerning this function of p38α MAPK, e.g. liver-specific inactivation 
of the p38α MAPK pathway showed enhanced hepatocyte proliferation and tumor 
development that correlated with upregulation of the JNK-cJun pathway, pointing 
towards a new mechanism whereby p38α MAPK negatively regulates cell 
proliferation by antagonizing the JNK-c-Jun pathway 71. However, the right tools in 
order to obtain a clearer picture of the p38α MAPK specific role in this function are 
still missing. One of these tools could be the p38αCA mouse model generated in this 
study. 
 
3.2.2 p38αKD Mice and their Applications 
The p38αKD model, as previously described, was generated by inserting a mutation 
(K53R) into the ATP-binding site of exon 2 of the p38α MAPK allele, which renders 
the synthesized protein catalytically and biologically inactive. Initial characterization 
of this mouse model has shown that the inversion of exon 2 to the mutated exon 2 is 
functional upon cre recombination. What remains to be shown now is the expression 
levels and the kinase inactivity of p38α MAPK in this model before it can be used for 
any further studies. 
In studies concerned with the kinase function of p38α MAPK, a mouse model 
expressing a kinase-dead form of p38α MAPK is an invaluable tool, since it can 
exclude the possibility of compensation by other p38 MAPK isoforms as the protein 
is synthesized normally but is not catalytically active. This could be an issue when 
using the knockout model where the protein is not expressed at all. Saying this, the 
p38αKD model can be used as a genetic tool to confirm the results from studies that 
have been performed with complete genetic ablation of p38α MAPK. The p38aKD 
mouse model is also interesting as a genetic tool, because it resembles more closely 
the effect caused by p38 inhibitors, which exert their effects by inhibiting the catalytic 
activity of the protein and not by altering its expression levels. Due to this fact, any 
results obtained with this mouse model, as opposed to models where p38α MAPK 
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has been deleted, can show a more realistic effect as to what would happen when 
using p38 inhibitors for the treatment of any number of diseases.  
Another intriguing possibility for the p38αKD model is its use in the study of the 
kinase-independent function of p38α MAPK. Use of RNAi but also small molecule 
p38 inhibitors to selectively inactivate p38α MAPK has revealed a novel function of 
this molecule in cell cycle progression that does not require its kinase activity 210. 
Therefore it appears that p38α MAPK has both kinase activity-dependant and kinase 
activity-independent functions. The kinase dependant functions of p38α MAPK have 
been well established, which cannot be said for its kinase-independent function. 
Saying this, both the p38αCA model together with the p38αKD model can be used, 
in conjunction with p38α knockout mice, to compare gene expression profiles in 
native conditions but also under various stimuli.  
 
3.3 Concluding Remarks 
In conclusion, we have investigated the macrophage and endothelial specific-role of 
p38α MAPK in the development of atherosclerosis and shown that it does not play a 
significant role in this disease, at least in the two cell types examined. In the case of 
macrophages this could be because of the regulating effect p38α MAPK has on 
JNK, which has also been shown to be strongly activated in atherosclerosis and to 
have a significant role in this disease by promoting foam cell formation 155. In the 
case of endothelial cells, where ablation of p38α MAPK also showed a reduction in 
JNK phosphorylation and thus activation, the lack of effect in atherosclerosis 
development could be due to the opposing roles that have been proposed for p38α 
MAPK in the endothelium, both pro-atherogenic and atheroprotective. However, this 
does not exclude the possibility that it can still have an important overall (systemic) 
role or a more pronounced role in another cell type involved in atherosclerosis 
development, like vascular smooth muscle cells, e.g., where it has been describe to 
be involved in their migration and proliferation 127. The effect of p38α MAPK ablation 
in other cell types important in atherosclerosis still remains to be investigated.  
Finally, we have successfully generated two new mouse models for p38α MAPK, 
p38αCA and p38αKD that are both invaluable tools for the further elucidation of the 
pathways this kinase is involved in.  
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4. Materials and Methods 
4.1 Design and Generation of p38αKD and p38αCA Mice  
4.1.1 Design and Generation of the Targeting Vectors  
4.1.1.1 Design of The Targeting Vectors 
 
p38αKD 
The p38αKD (kinase dead) targeting vector was designed to insert a lox66/lox71 160 
flanked switch cassette (exon 2 and mutated (K53R) exon 2 in opposing 
orientations) into the mouse p38α (MAPK 14) locus. The pEASY-FLIRT vector 
(Appendix I) was utilized as a base for generating the p38αKD targeting construct. 
This vector was initially digested with BamHI/AscI and purified to obtain a vector of 
4795 bp that contained a Herpes Simplex virus-thymidine kinase (HSV-TK) cassette 
for negative selection of clones with random integration of the targeting vector. PCR 
amplification of the vector pOG45 (plasmid #5, Pasparakis archive) using a 5’ primer 
containing a BamHI-lox66 sequence (sense) and a 3’ primer containing an AscI-SalI-
FRT sequence (antisense), generated a fragment containing a neomycin (NEO) 
resistance gene cassette flanked by two FRT sites. After digestion with BamHI/AscI, 
this fragment was subcloned into the previously digested pEASY-FLIRT vector. The 
Left and Right Arms of Homology (LAH and RAH respectively) were obtained from a 
p38α loxP-flanked targeting vector previously generated in our laboratory. The LAH 
(3722 bp) was obtained through BamHI digestion and immediately subcloned into 
the pEASY-FLIRT vector, whereas the RAH (3511 bp) was PCR-amplified with 
primers containing AscI sites, digested, and subsequently subcloned into the 
pEASY-FLIRT vector.  
The next steps in the generation of the targeting vector involved the insertion of the 
mutated lox71 site together with the inverted/mutated (K53R) exon 2 of the murine 
p38α allele. Initially, the 130 bp exon 2 flanked by 370 bp of intronic sequence on 
either side, was PCR-amplified with sense and antisense primers both containing a 
SalI site at the 5’ end. The fragment obtained was cloned into the pGEMT-EASY 
vector (Appendix II), in the orientation of the T7 polymerase. Mutagenesis of the 
plasmid was performed with PCR to insert a K53R mutation in exon 2, i.e. a lysine 
residue in the phosphate (ATP) binding pocket responsible for catalytic activity, 
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mutation of which has previously been shown to render p38α MAPK, and other 
kinases with this conserved region, catalytically inactive 211,212. The mutated 
(K53R) exon 2 was then PCR-amplified from the pGEMT-EASY vector with the use 
of a 5’ primer containing the sequence for SpeI-SalI-lox71-BamHI-EcoRI and a 3’ 
primer containing the sequence for SpeI. Digestion with SpeI and subcloning of the 
mutated fragment into the pGEMT-EASY vector containing the original exon 2 (not 
mutated) yielded a vector containing the original exon 2 and an inverted/mutated 
(K53R) exon 2 next to each other. This vector was then digested with SalI to extract 
the fragment containing the exon 2, the inverted/K53R exon 2 and lox71. The final 
targeting vector was obtained by subcloning this last fragment into the pEASY-FLIRT 
vector described above, to yield a ∼15 kb vector (Appendix III). All primers used were 
obtained from Metabion & Invitrogen, and all restriction enzymes from New England 
Biolabs. 
 
p38αCA 
The p38αCA targeting vector was designed to insert a constitutively active form of 
p38α MAPK into the mouse ROSA26 locus under the control of the endogenous 
ROSA26 promoter, but also a CAGS promoter (human cytomegalovirus very 
immediate early enhancer modified chicken β-actin promoter). The CAGS-ROSA26 
plasmid was a kind gift from Dr. Thomas Wuenderlich, from the Institute for 
Genetics, University of Cologne. The p38α cDNA was obtained from the pCMV5-p38 
plasmid kindly donated by the laboratory of Roger Davies, PCR-amplified with 
primers containing BamHI restriction sites, digested, and subcloned into the pGEX-
2T plasmid (Appendix IV). Using the DpnI mutagenesis protocol, five different 
mutations were inserted into the murine p38α MAPK cDNA, based on previously 
published mutations of the yeast homologue Hog1 that were shown to hyperactivate 
this protein 146,156. These mutants were tested for activity in two ways. Through an 
activity assay, where we tested for incorporation of radioactive phosphate in ATF2, a 
well known substrate of p38 that is activated by phosphorylation, and a dual-
luciferase reporter assay (described in another section).The most active mutant, 
D176A/Y323L, was identified. This was then PCR-amplified from the pGEX-2T 
vector and subcloned into the ROSA26-CAGS plasmid (Appendix IV), to yield a final 
targeting vector of ∼17kb. 
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4.1.1.2 Bacterial Cell Transformation 
DH5α E.coli bacterial cells (stored at -80˚C in 200 µl aliquots) were used for all 
transformations. Cells were thawed on ice, and 100 µl were mixed with 1-10 µl of 
ligation reaction. After sitting on ice for 30 mins, they were heat shocked at 42˚C for 
60-90 secs, and placed on ice for at least 2 mins. 1 ml of LB broth was added to the 
transformed bacteria, and they were allowed to grow at 37˚C for 1 hr, rotating. 1/10th 
of the volume was plated on 10cm3 bacterial plates containing agar, with the 
appropriate antibiotic resistance. The remaining volume was then spun down for 15 
secs, resuspended, and again plated on 10cm3 agar plates as above. 
 
4.1.1.3 DNA Minipreps 
DNA minipreps were prepared using the High Pure Plasmid Isolation Kit (Roche). 
According to the manufacturer’s instructions, 0.5-4 ml of bacterial culture in LB broth 
was harvested by centrifuging at 6000xg for 30 secs, and the pellet was 
resuspended in 250µl suspension buffer/RNAse. The cells were lysed by adding 
250µl Lysis Buffer, mixing gently and incubating for 5 mins at room temperature 
(RT). After 5 mins, 350µl Binding Buffer were added, and the bacterial lysate was 
mixed gently and allowed to stand on ice for 5 mins. The supernatant was collected 
after 10 mins of centrifugation at maximum speed, transferred to a High Pure filter 
tube and centrifuged at maximum speed for 30-60 secs. The flow through was 
discarded, and the DNA was washed by first adding 500µl Wash Buffer I and 
centrifuging at 13000xg for 1 min, then adding Wash Buffer II and centrifuging at 
13000xg again for 1 min, plus an additional min after discarding the flow through. 
Finally, the DNA was eluted by adding 100µl Elution Buffer and centrifuging at 
13000xg for 1 min. 
 
4.1.1.4 DNA Maxipreps 
DNA maxipreps were prepared using the QIAfilter Maxi Kit (Qiagen), according to 
the manufacturer’s protocol. In brief, 100 ml of overnight bacterial cell culture was 
harvested by centrifuging at 6000xg for 15 mins at 4˚C. The bacterial pellet was 
homogeneously resuspended in 10ml Buffer P1. Bacteria were lysed by  adding 
10ml of buffer P2, mixing thoroughly by vigorously inverting 4-6 times and incubating 
at room temperature for 5 mins, during which the QIAfilter Cartridges were prepared. 
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After the 5 min incubation, 10 ml of chilled Buffer P3 were added and the lysate was 
mixed thoroughly by inverting 4-6 times. Clearing of the bacterial lysate was 
performed by pouring the lysate into the barrel of the QIAfilter Cartridge, incubating 
at room temperature for 10 mins, and subsequently filtering the lysate into a 
previously equilibrated QIAGEN-tip 500 (10 ml buffer QBT) by gently inserting the 
plunger. The cleared lysate was allowed to enter the resin by gravity flow. Washing 
of the QIAGEN-tip was performed by adding 2 x 10 ml of Buffer QC. The DNA was 
then eluted for the QIAGEN-tip with 15 ml of Buffer QF, and precipitated by adding 
10.5 ml room temperature isopropanol, mixing, and centrifuging at 15000xg for 30 
mins at 4˚C. After carefully decanting the supernatant, the pellet was allowed to air-
dry for 5-10 mins. Finally, the DNA was redissolved in a suitable volume of buffer 
(200-300µl). DNA concentration was measured using a photometer. 
 
4.1.1.5 Gel Extraction and PCR Purification 
Gel extraction and PCR purifications were performed using the MACHEREY-NAGEL 
NucleoSpin Extract II Kit. For the gel extraction, the gel was cut out and weighed in a 
1.5 ml eppendorf tube. Buffer NT was added at a volume of 200µl/100mg of gel, and 
the gel was lysed at 50˚ C for 5-10 mins. For the PCR clean up this step was not 
required. In this case, buffer NT was added at a volume of 200µl/100µl PCR 
reaction. The DNA solution was then loaded onto the columns provided and 
centrifuged for 1 min to bind DNA. The silica membrane was washed with 600µl 
buffer NT3 by centrifuging for 1 min. After discarding the flow-through, the silica 
membrane was dried by centrifuging for 2 mins. The DNA was eluted by adding 30µl 
of dH2O, allowing the column to stand at RT for 1 min, and finally centrifuging again 
for 1 min. All centrifugation was performed at 11,000xg, RT. 
 
4.1.1.6 Mammalian Cell Transfection 
HEK293 (Human Embryonic Kidney cells) cells were used for all mammalian 
transfections. Transfections were performed with the use of Lipofectamine 2000, a 
proprietary formulation for the transfection of nucleic acids (DNA and RNA) into 
eukaryotic cells. HEK293 cells were grown on 6 well plates in DMEM medium, and 
transfected according to the manufacturer’s protocol, in serum free medium. 4µg of 
DNA was diluted in 50µl serum free medium, and mixed gently. 10µl of 
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Lipofectamine were diluted in 50µl serum free medium and incubated for 5 mins at 
RT. After 5 mins of incubation, the diluted DNA was combined with the 
Lipofectamine to give a total volume of 100µl. This solution was then mixed gently 
and incubated at RT for a further 20 mins, for the DNA to form complexes (micelles) 
with the Lipofectamine. After 20 mins, the 100µl of complexes were added to each 
well containing cells and 2ml serum free medium, and mixed gently by rocking. The 
cells were then incubated at 37˚C in a CO2 incubator for 18-48 hrs prior to testing for 
the transgene expression. The medium was changed after 4-6 hrs. 
 
4.1.1.7 p38 MAPK in vitro Kinase Assay 
Kinase assays were carried out using 0.2-0.4µg purified p38α MAPK, p38α MAPK 
mutants, or immunoprecipitates containing activated kinases were performed at 37˚C 
for 20 mins using 5µg of substrate (ATF2), 250µM ATP, and 10µCi of [γ-32P] ATP in 
20µl of kinase buffer (20mM Hepes, pH 7.6, 20mM MgCl2, 25mM β-
glycerophosphate, 0.1mM Na3VO4, and 2mM dithiothreitol (DTT)). The reactions 
were terminated with Laemmli sample buffer, and the products were resolved by 
SDS-PAGE and analyzed by autoradiography. The extent of ATF2 phosphorylation 
was quantified by phosphoimaging 157. 
 
4.1.1.8 Protein Immunoprecipitation 
HEK293 cells previously transfected with the wild-type and p38α MAPK mutants  
(pIRESPURO vector, Appendix VI) as described in the ‘Mammalian Cell 
Transfection’ section, were lysed in 1ml NP40 buffer (50 mM Tris-HCl pH 7.5, 
150mM NaCl, 1% NP40, 50mM NaF, 1mM NaVO3, 1mM DTT, 1mM EDTA, 
Complete tablet (Roche)), by rotating on a wheel at 4˚C for 1hr. After 1hr, the 
cytoplasmic protein extract was collected by centrifuging at 14000rpm/4˚C/10 mins to 
remove nuclei. Antibody was added to the cell lysates after determining protein 
concentration (use approximately 1 mg protein/IP), and the mix was incubated 
overnight at ˚C on a rotating wheel. The next day, pre-washed (2 x NP40 buffer) 
protein G beads were added to the protein/antibody mix (40µl 50% bead slurry / 
200µl lysate) and incubated for 1hr at 4˚C on a rotating wheel. Washing 3x with 
200µl NP40 buffer (without protease inhibitors) was performed by rotating for 10 
mins at 4˚C and subsequently centrifuging at 1200 rpm for 5 mins. The final bead 
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pellet was resuspended in 50% NP40 buffer. 20µl samples were kept throughout the 
procedure to check immunoprecipitation efficiency with western blotting. 
 
4.1.1.9 Isolation of Nuclear and Cytosolic Protein Extracts 
In order to prepare nuclear and cytosolic extracts, cells were centrifuged and 
resuspended in 0.5-1ml PBS, transferred to an eppendorf tube, on ice, and 
centrifuged at 6000 rpm for 1 min. The pellet was resuspended in 50-100µl buffer A 
(10mM HEPES pH 7.6, 10mM KCl, 2mM MgCl2 and 0.1mM EDTA) and incubated at 
4˚C for 10 mins (swelling step). Cells were lysed by adding 3.5µl/50µl of 10% NP40, 
mixed, and incubated at 4˚C for 1 min. The cytoplasmic fraction was recovered by 
centrifuging at 14000 rpm/4˚C/1min and collecting the supernatant. The remaining 
pellet was washed by resuspending in 50µl of buffer A and centrifuging 
14000rpm/15secs/4˚C. The supernatant was discarded and the nuclear fraction was 
extracted by adding 40µl buffer C (50mM HEPES pH 7.8, 50mM KCl, 300mM NaCl, 
0.1mM EDTA and 10% glycerol) to the pellet, resuspending it gently and incubating 
on ice for 30 mins. After 30 mins, the nuclear fraction was recovered by centrifuging 
at 14000rpm/5-10mins/4˚C, and collecting the supernatant. 
 
4.1.1.10 Dual-Luciferase Reporter Assay 
The dual luciferase system (Promega) was used to perform a reporter gene assay 
for p38 mutants in mammalian (HEK293) cells. In brief, HEK293 cells were grown 
and maintained at 37˚C in a CO2 incubator, in DMEM. Fresh medium was added 4 
hrs before the cells were co-transfected, as described in the ‘Mammalian Cell 
Transfection’ section, with wild-type or mutant p38α previously subcloned into the 
pIRESPURO vector, and the GAL4-responsive luciferase plasmids (kind gift from Dr. 
Jun Gu, Beijing University). Luciferase activity was measured 24 hrs later after 
transfection following the manufacturer’s instructions. 
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4.1.1.11 DpnI Mediated Site-Directed Mutagenesis 
Mutagenesis of the p38α cDNA was performed in the pGEX-2T vector, according to 
the DpnI mutagenesis protocol, using the primers listed below. The primers were 
designed according to the QuickChange Site-Directed Mutagenesis Kit, where it is 
stated that the primers should be between 25 and 45 bases in length and the melting 
temperature (Tm) should be greater than or equal to 78˚C.  
 
Forward (sense) primers 
Mutation Primer sequence 
(5’-3’) 
Length 
(bp) 
Tm 
(˚C) 
F327L gac cct tat gac cag tcc ttA gaa agc agg gac c 34 80.41 
Y323L gat gag cct gtt gct gac cct tTA gac cag tcc ttt 
gaa agc 
42 81.17 
D176A ggc tgg ctc ggc aca ctg CAg at gaga tga cag 
g 
34 79.87 
 
 
Reverse (antisense) primers 
Mutation Primer sequence 
(5’-3’) 
Length 
(bp) 
Tm 
(˚C) 
F327L ggt ccc tgc ttt cTa agg act ggt cat aag ggt c 34 80.41 
Y323L gct ttc aaa gga ctg gtc TAa agg gtc agc aac 
agg ctc atc 
42 81.17 
D176A cct gtc atc tca tcT Gca gtg tgc cga gcc agc c 34 79.87 
 
Mutagenesis of the p38α cDNA was performed by amplification in the pGEX-2T 
vector using the primers listed above. The reaction was setup as follows: 
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1x reaction 
(µl) 
DNA template plasmid  0.5 (5-20ng)
10µM Forward primer 0.5 
10µM Reverse primer 0.5 
Accuprime™ Pfx Supermix 
(Invitrogen) 22.5 
Total reaction volume 24 
 
The PCR conditions used for the amplification are listed below: 
95 ˚C               30 sec  
95 ˚C               30 sec 
55 ˚C               1 min 
68 ˚C               12 mins 
18 x 
 
After amplification, the methylated (parental) DNA was degraded with DpnI. This was 
accomplished by adding 1µl DpnI (10 units) to each PCR reaction and incubating at 
37˚C for 1 hr. The mutated vectors were then transformed into DH5α E.coli cells as 
described in the bacterial transformation section. Minipreps from 6 colonies were 
prepared for each mutation and sequenced to confirm the change. 
 
4.1.1.12 Sequencing 
All sequencing reactions were performed at the sequencing facility, at the Institute 
for Genetics, University of Cologne. The reactions and PCR programme used to 
amplify DNA for sequencing are listed below. 
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1 x reaction 
10µM primer  2 
Big Dye Terminator (Applied 
Biosystems) 6 
Template DNA 1 
dH2O 11 
Total reaction volume 20 
 
PCR programme 
95 ˚C               5 mins  
95 ˚C               15 sec 
52 ˚C               15 sec 
60 ˚C               3 mins 
32 x 
 
 
 
4.1.1.13 GST (Glutathione S-Transferase)-Purification of p38α MAPK Mutants 
for Activity Assays 
The p38α MAPK cDNA, as described above, was subcloned into the pGEX-2T 
vector, a GST Gene Fusion Vector that is specifically designed for high-level 
intracellular expression of genes or gene fragments as fusions with Schistostoma 
japonicum glutathione S-transferase. All p38α MAPK mutants were generated using 
this vector. Purification of GST-fused proteins was performed using Glutathione 
Sepharose 4B (Amersham Biosciences), designed for rapid single step purification of 
recombinant derivatives of glutathione S-transferases or glutathione dependant 
proteins. Frozen DH5α bacterial cell pellets were resuspended in 10 ml lysis buffer 
(0.1% Tx-100, 1mM EDTA and Complete protease tablet (1 tablet/50 ml), in PBS). 
Cells were then sonicated with MS72 tip 2 x 30 secs and dounced 20 times. This 
step was repeated twice. An aliquot of the lysate was centrifuged 30 
mins/9000rpm/4˚C. In the meantime, 500µl of bead glutathione bead slurry/ p38α 
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mutant was washed with 5 ml lysis buffer by centrifuging 5 mins, 1000 rpm. The 
supernatant of the previously centrifuged bacterial lysate was then added to the 
beads in a 15 ml Falcon tube, and the mix was rotated on a wheal at 4˚C for 1 hr, so 
the GST-fused proteins could bind to the beads. After 1hr, the beads were 
centrifuged 700rpm/5mins/4˚C. The supernatant was removed, and the beads were 
transferred into columns and washed extensively with lysis buffer without protease 
inhibitors. The last washes (5 ml) were performed in PBS with 1mM EDTA. GST-
fused proteins were eluted in 0.5 ml fractions with 20mM in PBS and 1mM EDTA. 
Samples were kept at all steps of the purification protocol. After running samples on 
an SDS gel, samples positive for the desired protein were pooled, dialyzed overnight 
in PBS at 4˚C, snap frozen in liquid nitrogen and stored at -80˚C. 
 
4.1.2 Transfection of ES Cells 
Bruce-4 Embryonic stem cells (ES) derived from C57BL/6 mice were grown on 
Mitomycin treated murine embryonic fibroblasts (feeder cells), previously plated on 
0.2% gelatin coated 10cm3 dishes in ES cell medium (Knockout-DMEM containing 
15% FCS (Fetal Calf Serum), 2mM L-glutamine, 0.1 mM non-essential amino acids, 
0.1% mM β-mercaptoethanol, 100u/ml penicillin/streptomycin, 1000u/ml LIF 
(Leukemia Inhibitory Factor)) at 37% in a CO2 incubator. 
Before transfection, cells were washed twice with PBS, harvested by trypsinization 
and resuspended in PBS at a final concentration of 1.25 x 107 cells/ml. 0.8 ml of the 
cell suspension were mixed with 25µg of the linearized targeting vector in a sterile 
1.5 ml tube, and allowed to stand for 5 mins at room temperature. The suspension 
was transferred to an electroporation cuvette and the cells were electroporated using 
the Bio-Rad Gene Pulser Xcellset at 230V, 500µF for one pulse (8.3 ms) at RT. After 
pulsing, the cell suspension was diluted in complete ES medium and plated on three 
10cm3 dishes containing feeder cells. Neomycin selection started 24 hrs after 
electroporation by applying 0.2mg/ml G418, on both p38αKD and p38αCA 
transfected ES cells. Negative selection (thymidine kinase) started 6 days after 
electroporation by applying 2 x 10-6 Ganciclovir to p38αKD transfected cells only. 
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4.1.3 Picking of Clones 
ES cells were fed every day with complete ES medium. After having reached a 
visible size (normally 8 days) single cell clones were picked and expanded in 96-well 
plates on feeders in selection medium. Once the cells approached confluency, they 
were washed twice with PBS and trypsinized with 25µl trypsin-EDTA for 5mins at 
37˚C. 100µl of ES medium was added in each well, cells were dissociated by 
vigorous pipetting and the content of each well was split in three feeder cell 
containing 96-well plates. From these plates, two were frozen at -80˚C 24 and 48hrs 
later, and one was further split into three gelatinized 96-well plates without feeders 
for DNA analysis. 
 
4.1.4 Preparation of DNA and Southern Blot Analysis 
In order to prepare genomic DNA from ES cell clones, cells were grown until fully 
confluent in gelatinized 96-well plates, washed with PBS and lysed with 50µl lysis 
buffer (10mM NaCl, 10mM Tris-HCl pH 7.5, 10mM EDTA, 0.5% Sarcosyl, 0.4-
1mg/ml freshly added proteinase K) overnight at 56˚C in a humidified chamber. The 
next day, the box was cooled for 1hr at RT and genomic DNA was precipitated by 
adding 100µl of 100% EtOH to each well and allowing it to stand for 1-2hrs at RT. 
Once the filamentous DNA was visible, the plate was gently inverted to remove the 
EtOH, washed with 70% EtOH and air dried for 15 mins. Finally, the DNA was 
dissolved in 35µl of the digestion mix (1X restriction buffer, 1mM spermidine, 1mM 
DTT, 100µg/ml BSA, 50µg/ml RNase A and 50U of restriction enzyme/reaction) and 
incubated overnight at the appropriate temperature (37˚C) in a humidified 
atmosphere. The DNA fragments were separated on a 0.8% agarose gel that was 
denatured by soaking it for 45 mins in Denaturing solution (0.4M NaOH, 0.7% NaCl) 
and transferred overnight by capillary flow onto the surface of a charged nylon 
membrane (Hybond-XL, Amersham). The following day, the membrane was soaked 
for 2 mins in Neutralization solution (0.5M Tris-HCl pH 7.0), baked at 70˚C for 1 hr 
and pre-incubated in hybridization buffer (1M NaCl, 50Mm Tris-HCl pH, 10% 
dextransulphate, 1% SDS, 250µg/ml Salmon Sperm DNA) at 65˚C for 1hr. DNA 
probes labeled by random priming with 32Pα-dGTP were added to the hybridization 
buffer and allowed to hybridize to the membrane overnight at 65˚C. The next day the 
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membrane was washed in wash buffer (1mM EDTA, 40Mm Na-phosphate pH 7.2, 
1% SDS) at 65˚C and exposed to autoradiographic film.  
 
4.1.5 Screening for Positive ES Cell Clones 
Out of 384 G418 and gancyclovir-resistant clones, 4 were identified as homologous 
recombinants by Southern Blot analysis of ES cell DNA digested with BamHI and 
probed with a 5’ and 3’ probe, for p38αKD. For p38αCA we identified 9 clones 
positive out of 192 picked clones where homologous recombination had occurred, by 
Southern blot analysis of ES cell DNA digested with EcoRI and probed with a R26 5’ 
probe. DNA fragments used as probes for the p38αKD targeting were amplified from 
a BAC containing the murine p38α MAPK gene. The 700 bp DNA fragment used as 
a 5’ probe for the p38αCA targeting was digested from the Orlein plasmid, with an 
EcoRI/PacI digestion. A NEO probe was also used in both cases to check for 
random integration. 
For the p38αCA targeting, positive clones were also confirmed by treating ES cells in 
vitro with HTNC and looking at GFP expression by FACS analysis, as described in 
another section below. 
The sequences of the primers and PCR programme used to amplify the probes for 
the p38αKD targeting are listed below. All probes were amplified using the 
Accuprime™ Pfx Supermix (Invitrogen). 
 
Primers 
Primer Sequence 
(5’-3’) 
Length 
(bp) 
Tm 
(˚C)
5’ probe sense GAT AGG GAG AGG AAG CAG CAT GTT AG 26 60 
5’ probe antisense CAT GGA GGC CAT TCG TCG AGT GAG ATA 
C 
28 60 
3’ probe sense GTT CTA GGA CAG CCA GGG TTA CAC AGA 
G 
28 63 
3’ probe antisense GTG AGA GAG AAT CCT TCC AGC CCC TTA C 28 63 
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PCR Programme 
95 ˚C               5 mins  
95 ˚C               15 secs 
55 ˚C               30 secs 
68 ˚C               30 secs 
35 x 
 
4.1.5.1 HTNC Treatment and FACS Analysis of p38αCA Targeted ES Cells 
ES cells transfected with the p38αCA targeting vector, and found positive for 
homologous recombination with Southern Blotting analysis, were plated on 6-well 
plates on a confluent layer of Mitomycin-treated feeder cells, at a confluency of 2 x 
105 cells/well. After allowing the cells to attach for 5 hrs, they were washed twice with 
PBS, and 5 or 10µM HTNC was added in Knockout-DMEM/PBS 1:1, supplemented 
with 100U/ml penicillin/streptomycin, for 16-20 hrs. Controls were ES cells treated 
with Knockout-DMEM/PBS 1:1, without HTNC. After 16-20 hrs, the cells were 
washed twice with PBS again and allowed to recover for 2-3 days in complete ES 
cell medium. On day 3, the cells were scraped off in PBS and FACS analysis was 
performed for GFP expression. 
 
4.1.6 Blastocyst Injections and Germline Transmission 
Chimeric mice were generated by injection of positive ES cell clones (still containing 
the NEO cassette) into blastocysts from C57Bl/6 or CB20 mice. Matings of male 
chimeras to C57Bl/6 females yielded offspring with germline transmission. 
p38αKDFL/wt mice were generated by crossing p38αKDNEOFL/wt mice with Flp-Deleter 
mice to remove the NEO cassette. p38αKDFL/FL mice are now being generated by 
crossing p38αKDFL/wt mice with each other. For the p38αCA mice, the NEO cassette 
was not necessary to remove. R26wt/p38αCAFL/ mice are currently being crossed 
with Cre-Deleter mice, but also Alfp- Cre mice. Hepatocytes were isolated from 
R26wt/p38αCAFL positive for AlfpCre (R26wt/p38αCALPC-KO) to examine GFP 
expression. 
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4.1.6.1 Hepatocyte Isolation from R26wt/p38αCALPC-KO Mice for FACS Analysis 
Mice used for the isolation of hepatocytes were anaesthetized with 
Ketamin/Rompum (Avertin) (∼ 12μl/gr bodyweight) and the abdominal cavity was 
opened. A bornyle was passed into the vena cava and connected with a pump, once 
the bornyle had been filled with blood in order to avoid bubbles. After cutting the 
portal vein, mice were perfused with Solution I (EBSS -Ca/+Mg (GIBCO), 0.5mM 
EGTA) at a speed of 7-8 for 20 secs. Once the liver had turned pale (within secs), 
the perfusion rate was reduced to a speed of 5 and perfusion was allowed to go on 
for 5 more mins. After 5 mins, the pump was stopped, the solution was exchanged 
for 50 ml Solution III (Solution II, Collagenase Type II (Worthington) and trypsin 
inhibitor (Sigma)) and the perfusion was restarted at a speed of 4-5. After perfusing 
with 50ml Solution III the liver was extracted and transferred into ∼10ml of ice cold 
Solution II (EBSS +Ca/+Mg (GIBCO), 10mM HEPES). In a petri dish, the capsule of 
the liver was peeled away and the cells were carefully brushed out with a cell 
scraper. The cells were then passed through a 22μm nylon mesh and spun at 500 
rpm for 5 mins. After washing 2x with high glucose DMEM or Williams E (5% FCS), 
the viable cells were counted and seeded at a density of ∼ 2.5x105 cells per 6-well 
collagen coated plate or immediately used for FACS analysis. The medium on the 
seeded cells was changed after 4 hrs. 
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4.2 Generation and Analysis of Macrophage and 
Endothelial-Specific p38α MAPK Knockout Mice in 
Atherosclerosis  
4.2.1 Generation of Mice for Atherosclerosis Studies and Diet 
The p38α MAPK mice with IoxP-flanked alleles used in this study were previously 
described elsewhere 75. p38αFL mice were crossed with LysMCre 147 and 
Tie2ERT2Cre 74 transgenic mice to generate myeloid and endothelial cell-specific 
knockouts, respectively. These mice were then crossed into ApoE-/- mice to render 
them susceptible to atherosclerosis development. For induction of Cre activity, mice 
carrying the Tie2-ERT2 transgene and their Cre negative littermates were fed a 
tamoxifen-containing diet as has been previously described 213. At the age of 6-8 
weeks in both models, male and female littermates were placed on a cholesterol rich 
‘western–type’ diet (Harland Tekland) for 10 weeks, to develop atherosclerosis.  All 
animal procedures were conducted in accordance with European, national, and 
institutional guidelines, and protocols and were approved by local governmental 
authorities.  
 
4.2.2 Analysis of Atherosclerosis 
4.2.2.1 Histology of Plaques and Lesion Size 
Consecutive 7 μm sections of the heart in the atrioventricular valve region were 
collected and stained with toluidine blue, as described previously (Kanters et al., 
2003). For morphometric analysis lesion size was measured on four consecutive 
sections in 42 μM intervals using Adobe Photoshop. 
 
4.2.2.2 En face Analysis of Atherosclerosis 
Sudan IV staining and en face analysis of atherosclerotic lesions were performed as 
described previously by Holman et al., 1958 214. Plaque areas were quantified with 
Adobe Photoshop.  
 
4.2.2.3 Lipid Analysis 
Cholesterol measurements were performed using the CHOL reagent (Roche) and 
reading absorbance at 500 nm, on plasma, after overnight fasting. 
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4.2.2.4 Immunostainings 
Frozen sections of the aortic root were fixed in ice-cold acetone for 10 minutes, dried 
under a ventilator, and washed with PBS. Sections were blocked in 4% fetal calf 
serum (FCS) with Avidin D solution (Avidin/Biotin Blocking Kit; Vector Laboratories) 
for 30 mins. Primary antibodies were incubated for 60 minutes (anti-mouse 
macrophages/ monocytes MCA519GT, rat, 1:1000 dilution, Serotec) in 4% FCS 
solution with Biotin (Avidin/Biotin Blocking Kit; Vector Laboratories). Sections were 
washed with PBS and incubated with Biotin-conjugated secondary antibody rabbit 
anti-rat/ biotinylated E0468, 1:100, DakoCytomation) in 4% FCS/ 2% normal mouse 
serum (NMS) for 60 minutes. After washing, sections were further incubated in a 
1:50 Avidin/ 1:50 Biotin solution in PBS (Vectastain ABC Kit, Vector Laboratories). 
Sections were washed again and staining was visualized by incubation with AEC 
(AEC Kit, Vector Laboratories) and counterstaining with haematoxylin. Mounting of 
the sections was performed with Entellon (MERCK) mounting medium.  
Staining for collagen on frozen sections of the aortic root was performed by using the 
Masson Trichrome staining kit (Sigma Aldrich) according to the instructions of the 
manufacturer. 
4.2.2.5 Quantitative Real-Time PCR 
RNA was isolated from aortas, but also macrophages and endothelial cells in in vitro 
experiments, using Trizol-reagent (Invitrogen) and RNeasy columns (QIAGEN). RNA 
(1 μg) was used for reverse transcription with SuperScript III reverse transcriptase 
(Invitrogen). The reaction was topped up to 200 μl with water, and 2 μl were used for 
quantitative real-time PCR reaction either with Power SYBR Green Kit (Applied 
Biosystems) or with TaqMan qPCR Kit from Eurogentec. Standardization was 
performed with primers for ubiquitin (SYBR Green) or GAPDH (TaqMan). VCAM-1, 
IL-1β, TNF, RANTES, MCP-1, MIP-1α, MIP-1β, MIP-2α, MCP-3, MMP-13, IP-10, IL-
6, etc. were quantified with the respective TaqMan probes from Applied Biosystems. 
The other primer sequences are available upon request.  
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4.2.3 In vitro Experiments 
4.2.3.1 Cell Culture 
Bone marrow-derived macrophages 
Bone marrow–derived macrophages (BMDM) were obtained according to standard 
procedures described elsewhere 215. Bone marrow cells were subjected to red 
blood cell lysis and plated on 10 cm3 bacterial Petri dishes (Greiner) in RPMI 
Glutamax (Invitrogen) supplemented with 10% FCS penicillin/streptomycin and 20% 
L929 conditioned medium. The cells were cultured for 8 days before experiments 
were performed.  
 
Thioglycolate-elicited peritoneal macrophages 
For isolation of thioglycolate-elicited peritoneal macrophages, mice were injected 
intraperitoneally with 1 ml of sterile thioglycollate broth (4% wt/vol). After 3-4 days, 
cells were isolated by flushing the peritoneum with 8 ml ice-cold PBS. Red blood 
cells were lysed and the remaining cells were extensively washed using ice-cold 
PBS. Cells were seeded on bacterial Petri dishes (Greiner).  
 
Lung endothelial cells 
After perfusion with PBS, lungs were dissected from mice, passed through 75% 
ethanol for 10 secs and placed in fresh DMEM (Gibco). Using a blade, the lungs 
were cut into very small pieces to produce a pate consistency and subsequently 
incubated in 0.2% collagenase (Gibco) in DPBS+ CaCl2 (Gibco) for 1hr at 37˚ C. 
After 1 hr, the solution was passed through a 19G needle to break down remaining 
tissue and passed through a 70µM cell strainer. The cell suspension was then 
centrifuged at 1500 rpm for 5 mins. The remaining pellet was resuspended in 
endothelial cell medium (DMEM low glucose: Ham’s F-12 1:1, 20% FCS, 50µg/ml 
endothelial mitogen, 25µg/ ml heparin, 100U/ml penicillin/streptomycin and 2mM 
glutamine) and plated on a T75 flask (Corning) previously coated with coating 
medium (0.1% gelatin, 1. A negative (LEAF rat anti-mouse CD16/32, 1:2000 dilution, 
Biolegend) and positive (CD102 rat anti-mouse, 1.5:2000 dilution, BD Biosciences) 
sort with Dynabeads (sheep anti-rat IgG, Invitrogen) allowed us to obtain pure 
populations of endothelial cells. Purity of endothelial cell population was assessed by 
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staining with the mouse endothelial cell marker CD146 (Miltenyi Biotec) and 
performing FACS analysis. 
 
4.2.3.2 Oxidized LDL Stimulation  
Oxidation and fluorescence labeling of LDL 
LDL was oxidized (oxLDL) as previously described 216. Briefly, human LDL (600 µl 
of 250 μg/ml) (Applichem) was incubated with CuSO4 (22.5 μl of 1.6mM) in PBS for 
9hrs at 37°C. The oxidation reaction was stopped with an excess of EDTA (100 μl of 
0.5 M), and the LDL was dialyzed O/N in PBS at 4 °C. For assessment of oxLDL 
uptake in macrophages by FACS analysis, oxLDL was subsequently labeled with DiI 
217 for 18 hrs at 37°C by adding 300μg DiI in DMSO/ mg LDL. The oxLDL-DiI 
solution was then dialyzed against PBS O/N at 4 °C and the next day centrifuged at 
10.000 rpm/15 mins to remove any precipitate.  
 
OxLDL stimulation of peritoneal macrophages 
OxLDL stimulation of peritoneal macrophages was performed as described 
previously 155. Briefly, Thioglycolate-elicited peritoneal macrophages were plated on 
6 well bacterial plates in RPMI 1640 medium supplied with 10% FCS. After 2 hours, 
non-adherent cells were washed out and macrophages were starved for 48h. Then, 
fluorescence-labeled oxLDL (DiI-oxLDL) (50μg/ml) (Applichem) was added to the 
medium. After 2.5 hours cells were stained overnight with Oil-red O and costained 
with hematoxylin for 20 seconds to visualize foam cell formation. Uptake of oxLDL 
was quantified by FACs analysis. Scavenger receptor and cytokine, chemokine and 
MMP expression was assessed by collecting RNA and performing RT-PCR as 
described previously. 
 
OxLDL stimulation of lung endothelial cells 
Lung endothelial cells were isolated from p38αFL/FL/ApoE-/- mice as described above. 
At passage 8, they were either treated or not treated with HTNC overnight (16 hrs) in 
DMEM (low glucose): PBS 1:1 with 100U/ml penicillin/streptomycin. The next day 
HTNC was removed and replaced with normal endothelial cell medium. The cells 
were allowed to reach confluency and split 1-2 more timed before being used for any 
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experiments to ensure that they were not previously activated due to the Cre. For 
oxLDL stimulation, the cells were starved overnight in starving medium (endothelial 
cell medium supplemented with 2% FCS, without endothelial mitogen). The next day, 
100µg/ml oxLDL was added to the medium for indicated timepoints. Cells were 
centrifuged 3000rpm/5 minutes and pellets collected for protein lysates. 
 
4.2.3.3 MACS Sorting of Lung Endothelial Cells 
Lung endothelial cells were isolated from female p38αEC-KO/ApoE-/- and ApoE-/- 
littermates that had been previously fed a tamoxifen diet for 5 weeks to induce cre 
expression, and subsequently fed a cholesterol rich ‘western diet’ for 10 weeks, as 
described above. After passing the collagenase dissociated lung through a 19G 
needle, the cell suspension was passed through a 100µm, then a 70µm and a 40µm 
cell strainer and cells were collected in a 50ml tube (Falcon). Cells were washed 
twice with PBS by centrifuging 300xg/10 mins. Removal of debris and cell 
enrichment was achieved by mixing cell suspension with 30% Histodenz solution 
(Sigma-Aldrich, and centrifuging 1500xg/2mins. Low-density cells at the interface 
were harvested and washed twice in degassed MACS buffer (PBS pH 7.2, 0.5% 
BSA and 2mM EDTA). Cells were resuspended in MACS buffer (90µl/107 cells) and 
labeled with Anti-LSEC MicroBeads (beads coupled to the mouse endothelial cell 
marker CD146, Miltenyi Biotec) by adding 10µl beads/ 107 cells and incubating 15 
mins/ 4˚C. After washing, the cells were resuspended in 500µl buffer/108 cells. 
Magnetic separation of the cells was performed by use of an MACS column (MS, 
Miltenyi Biotec) and a magnetic field. Once the cell suspension was loaded onto the 
column, magnetically labeled cells (endothelial cells) were retained on the column, 
whereas unlabelled cells (CD146 negative fraction) ran through. After removal of the 
column from the magnetic field, the magnetically retained cells were eluted (CD146 
positive fraction). CD146 sorting of lung endothelial cells was confirmed through 
FACS analysis. Protein lysates were prepared from sorted cells in order to perform 
immunobloting. 
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4.2.3.4 Whole Cell Protein Extraction 
Whole cell protein extracts were prepared from endothelial cells and macrophages 
by lysing with high salt RIPA buffer. In general, after harvesting cells by washing 2 x 
PBS, cells were scraped off plates in PBS and collected by centrifuging at 6000 rpm 
for 5 mins at 4˚C. The PBS was aspirated and the cell pellet was resuspended in 50-
100µl high salt RIPA buffer (20 mM Hepes, 350 mM NaCl, 20% Glycerol, 1mM 
MgCl2, 0.5mM EDTA, 0.1 mM EGTA, 0.1% NP40, 1mM DTT, 1mM NaVO3, 1mM 
NaF, and 1 mini Complete tablet/10 ml). The cell suspension was mixed thoroughly 
by pipetting and vortexing, and lysed by incubating 30 mins on ice and sonicating 7.5 
mins in a cooled sonicating bath. Protein extracts were collected by centrifuging at 
maximum speed (14000 rpm) for 20 mins at 4˚C and collecting the supernatant. 
Protein concentration was measured by Bradford assay, at 595 nm, and extracts 
were prepared for SDS gel analysis by boiling for 5 mins with SDS sample buffer. 
 
4.2.3.5 Immunoblot analysis 
Protein lysates were prepared from macrophage and endothelial cells, separated by 
SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose and analysed 
by immunoblotting. Membranes were probed with antibodies specific for: α-tubulin 
(Sigma-Aldrich, T6074), p38α (Cell signaling, #9218), p-p38 (Cell Signaling, #9211), 
p-JNK (Cell Signaling, #9251) and JNK (Cell Signaling, #9252). Horseradish 
peroxidase-conjugated anti-rabbit, anti-mouse and anti-rat secondary antibodies 
were used (Amersham). 
 
4.2.3.6 Statistical Analysis 
All statistical analyses were performed using Prism program (GraphPad Software 
Inc., San Diego, CA), and Excel. Statistical significance between experimental 
groups was assessed using an unpaired two sample Student’s t test. 
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4.3 Genomic DNA Isolation from Mutant Mice and Genotyping 
4.3.1 Genomic DNA isolation from Mutant Mice 
Genomic DNA was isolated from 5mm tail taken from 3-week old pups, after 
overnight digestion in 500 µl of Tail buffer (100mM Tris-HCl, pH 8.5, 200mM NaCl, 
5mM EDTA, 0.2% SDS) with 200µg/ml proteinase K at 56˚C. The following day, the 
digested tails were centrifuged at 14.000 rpm for 5 mins. The supernatant was 
transferred to a fresh tube, and genomic DNA was extracted by mixing with an equal 
volume of isopropanol and allowing it to precipitate. After centrifuging 14000 rpm for 
5 mins to pellet DNA, it was washed in 70%, air dried and resuspended in 50-100µl 
Tris-EDTA (TE). 2µl of resuspended DNA was used for each PCR reaction. 
 
4.3.2 Genotyping PCR Protocols 
Genotyping on murine genomic tail DNA was performed using the primers listed 
below: 
PCR 
Primers 
(Pasparakis database #) 
(5’-3’) 
Annealing 
Tm 
(˚C) 
Expected bands 
(bp) 
p38αKD 
# 1823: GCT GAA GCA CAT GAA ACA CG 
# 1824: GCA AAG AGT GGG GGT TAC 
# 1825: CTG AAA CGG TCT CGA CAG C 
60 
Wt 430 
Floxed 512 
Floxed/Inverted 552 
 
p38αKD 
Neo 
# 697: GAT TCG CAG CGC ATC GCC 
# 1822: GAT GCC CCG TCT TTG TAT C 
62 Neo +ve 531 
General 
Cre 
# 101: GTC CAA TTT ACT GAC CGT ACA C 
# 102: CTG TCA CTT GGT CGT GGC AGC 
61 Cre +ve 350 
ApoE 
# 363: GCC TAG CCG AGG GAG AGC CG 
# 364: TGT GAC TTG GGA GCT CTG CAG C 
# 365: GCC GCC CCG ACT GCA TCT 
68 
Wt 155 
Ko 245 
Flp-
Deleter 
# 483: TTA GTT CAG CAG CAC ATG ATG 
# 608: GGA GGA TTT GAT ATT CAC CTG 
54 Flp +ve 450 
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Deleter 
Cre 
# 750: CGC ATA ACC AGT GAA ACA GCA T 
# 745: GAA AGT CGA GTA GGC GTG TAC G 
58 Cre +ve 600 
Alfp-Cre 
# 831: TCC AGA TGG CAA ACA TAC GC  
# 699: GTG TAC GGT CAG TAA ATT GGA C 
60 Cre +ve 300 
LysM-Cre 
# 741: CTT GGG CTG CCA GAA TTT CTC 
# 742: TTA CAG TCG GCC AGG CTG AC 
# 743: CCC AGA AAT GCC AGA TTA CG 
63 
Wt 350 
Cre +ve 700 
p38 
# 688: CTA CAG AAT GCA CCT CGG ATG 
# 689: AGA AGG CTG GAT TTG CAC AAG 
# 690: CCA GCA CTT GGA AGG CTA TTC 
62 
Wt 121 
Floxed 188 
Deleted 411 
CAGS 
ROSA26 
# 878: TGT CGC AAA TTA ACT GTG AAT C 
# R26 RV: GAT ATG AAG TAC TGG GCT CTT 
# R26 FW: AAA GTC GCT CTG AGT TGT TAT 
C 
56 
Wt 570 
Floxed 380 
 
All the genotyping reactions were setup as listed below: 
 1x reaction (µl) 
10 x Taq buffer 3 
2mM dNTPs  3 
10 x Primer mix (33 µM) 3 
25 mM MgCl2 1.8 
Tail DNA 2 
5 U/µl Taq 0.2 
dH20 17 
Total reaction volume 30 
 
The general PCR programme used can be seen below. Annealing temperatures for 
each genotyping reaction were as listed in the primers table above. 
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94 ˚C               3 mins  
94 ˚C               30 sec 
Annealing        30 sec 
72 ˚C               30 sec 
35 x 
72 ˚C               3 mins  
 
Some special settings were required for the CAGS ROSA26, the LysMCre, ApoE 
and Deleter Cre PCRs. These are listed below. 
 
CAGS ROSA26 
94 ˚C               3 mins  
94 ˚C               30 sec 
Annealing        45 sec 
72 ˚C               1.5 mins 
45 x 
72 ˚C               10 mins  
 
LysMCre 
94 ˚C               3 mins  
94 ˚C               30 sec 
Annealing        30 sec 
72 ˚C               1.4 mins 
35 x 
72 ˚C               5 mins  
 
ApoE 
94 ˚C               3 mins  
94 ˚C               20 sec 
Annealing        40 sec 
72 ˚C               30 sec 
30 x 
72 ˚C               3 mins  
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Deleter Cre 
94 ˚C               3 mins  
94 ˚C               30 sec 
Annealing        30 sec 
72 ˚C               1 min 
35 x 
72 ˚C               3 mins  
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pEASY-FLIRT
9261 bp
Flp CDS
PGK Neo R
HSV-TK
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Ace promoter
LoxP
LoxP
frt
frt
AscI (4487)
BamHI (21)
SalI (4432)
 
 
 
 
EcoRI (1809)
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AMPr
pUC/M13 forw ard
pUC/M13 rev erse
T7 forw ard
M13 rev erse
T7 promoter
SP6 promoter
SalI (91)
SpeI (65)
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FRT
FRT
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lox71 INV
Exon 2
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Lox66
TK-NEO
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